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Abstract 
Contemporary diagnostic techniques for prostate cancer (PCa) have a limited ability to 
distinguish between benign and malignant disease. The ghrelin receptor has a differential 
expression in normal, benign and cancerous prostatic tissue. Targeting this receptor with 18F-
radiolabelled peptidomimetics would enable differentiation between these disease states via 
PET imaging. A series of 19F-peptidomimetics were synthesized and characterized by 
HRMS, HPLC and 1H-NMR spectroscopy in order to test locations for 18F radioisotope 
insertion. Competitive receptor binding assays using HEK293/GHS-R1a cells were used to 
evaluate compound binding affinities. This led to the identification of two lead compounds: 
[1-Nal4,Lys5(4-FB)]G-7039 (IC50 = 69 nM) and [Lys5(2-FP)]G-7039 (IC50 = 19 nM). 
Prosthetic group radiolabelling of [1-Nal4,Lys5(4-FB)]G-7039 using N-succinimidyl 4-
[18F]fluorobenzoate gave radiochemical yields of 51-52%, radio-purity > 98% and specific 
activity of 116 MBq/μmol after 127 minutes at end-of-synthesis. Successful 18F-
radiolabelling of [1-Nal4,Lys5(4-FB)]G-7039 highlights its potential for use as a PET 
imaging agent for early-stage PCa diagnosis. 
  
Keywords 
Molecular imaging, prostate cancer, positron emission tomography, imaging agents, growth 
hormone secretagogues, ghrelin receptor agonists, GHS-R1a, ghrelin, peptidomimetics, 
solid-phase peptide synthesis, 18F-radiolabelling, G-protein coupled receptors.  
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Chapter 1  
Molecular Imaging 
1.1 Introduction 
The field of molecular imaging, despite existing for only 15-20 years,1 is enabling both 
researchers and clinicians to better observe and understand the intricate biochemical 
activities that occur inside living systems.2 Defined as the real-time observation, 
identification, and quantification of cellular and subcellular biological and chemical 
events within living organisms,2, 3 it utilizes unique instrumentation and imaging 
modalities that interrogate the mechanisms of disease progression and human 
physiology.2 Molecular imaging is considered to be a multidisciplinary field with 
contributions from areas such as chemistry, molecular biology, engineering, 
biochemistry, physics and many others.2 One of its main aims is to attempt to overcome 
the limitations of in vitro biological assays by non-invasively studying intact living 
organisms and cellular processes without affecting the system under investigation.2 
Figure 1 illustrates the typical steps involved in a molecular imaging study. The first step 
requires the selection of a pathology or biochemical process of interest.2 Having 
determined whether this process or disease state may be studied by molecular imaging, a 
molecular target which would allow either direct or indirect visualization of this 
phenomenon is chosen (step 2).2 This may be a G-protein coupled receptor (GPCR) 
overexpressed in a particular cancer (e.g. the gastrin-releasing peptide receptor; GRPr, in 
breast cancer4) or a cellular event, such as glucose metabolism.5 Careful choice of 
imaging modality then ensues (step 3). These modalities include (but are not limited to) 
positron emission tomography (PET), single-photon emission computed tomography 
(SPECT) and magnetic resonance imaging (MRI).2 Depending on the type of imaging 
method employed, the order of subsequent steps will vary. For example, development of 
an MRI contrast agent would require the synthesis of the probe, in vitro testing and an 
animal study (4, 5 and 7) followed by eventual imaging in humans (8). For a SPECT or 
PET imaging agent, synthesis would be followed by a series of in vitro tests to check the 
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stability of the probe and target specificity (5). This could result in a change in the 
structure of the imaging agent. In any case, labelling with a positron-emitting 
radioisotope would then ensue (6), along with an animal study (step 7, a murine model is 
the usual starting point) and finally, the image acquisition and processing step (8).2  
 
Figure 1. The key steps of a molecular imaging study. 
1.2 Prostate Cancer 
As can be seen in Figure 1 above, a molecular imaging study often begins with the 
identification of a specific disease process. A considerable variety of pathologies exist 
but of particular interest to this thesis is prostate cancer (PCa). This carcinoma is the 
foremost male malignancy in North America.6 In Canada in 2013 it was estimated that 
prostate cancer represented 25% of all new cancer cases and 10% of all cancer deaths in 
men.7 Despite the absence of a single cause for PCa, a number of potential risk factors do 
exist.8 These include inherited gene mutations and diets high in fat, processed meat and 
dairy products.8 The prostate may be divided up into three specific regions that assist in 
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tumour localization: the peripheral zone (p-zone), the central zone (c-zone) and the small 
transitional zone (t-zone).9, 10 Approximately 75% of malignant tumours originate in the 
p-zone.10, 11 Benign tumours (which lead to the state known as benign prostatic 
hyperplasia, BPH) are found exclusively in the t-zone.9, 10 Clinical methods currently 
used to diagnose PCa involve a combination of the digital rectal examination (DRE), the 
serum prostate-specific antigen (PSA) test and trans-rectal ultrasound (TRUS)-guided 
biopsy.10 These methods are not only used to predict the recurrence of tumours after 
radical prostatectomy12 and the potential for cancer to spread from the prostate,13 but also 
to divide patients into groups based on the risk of PCa reappearance after localized 
treatment.14, 15 Despite the utility that these techniques provide, the presence of sampling 
error in TRUS-guided biopsies15 coupled with patients who have consistently elevated 
levels of serum PSA in spite of negative prostate biopsies,10 suggests that developing 
non-invasive imaging methods to improve disease identification at an earlier phase of 
illness is crucial.15  
1.3 Imaging Modalities 
There are a number of different methodologies in current use that could be applied to 
imaging prostate cancer. One such non-invasive technique for PCa diagnosis and staging 
is a combination of MRI and functional MRI methods such as diffusion-weighted MRI 
(DW-MRI), magnetic resonance spectroscopic imaging (MRSI) and dynamic contrast-
enhanced MRI (DCE-MRI).10 Briefly, these methodologies collect information on in vivo 
diffusion coefficients for biological tissues, metabolism and tissue vascularity 
respectively.10 The combination of T2-weighted MRI and two or more functional 
techniques make up the multi-parametric prostate MRI (mpMRI) exam, which is 
currently a highly effective way to identify and localize PCa.15 Despite the usefulness of 
the data gathered by functional MRI, it tends to suffer from difficult and lengthy 
procedures (for MRSI),15 limited lesion detection in the central gland,16 the requirement 
for dedicated computer software for data analysis (DCE-MRI)15 and the inability to 
specify cut-off values in apparent diffusion coefficients in DW-MRI, thus making the 
delineation between benign and malignant tumours problematic.15, 17 In addition to these 
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factors, there are currently no guidelines available that specify which functional sequence 
is most appropriate in a particular clinical scenario.10  
Alternative techniques for cancer imaging such as computed tomography (CT) have been 
in clinical use since the 1970s. This method utilizes high energy X-rays to give high 
resolution morphological and anatomical information about a specific region of interest, 
thus enabling tumour localization and identification.2, 18 Unfortunately, CT is not capable 
of differentiating between PCa and BPH and also has trouble diagnosing primary PCa.18, 
19 In addition, CT scans expose patients to high levels of radiation, further reducing the 
utility of this method. This is because the quantity of scans that can be carried out on a 
specific patient in a set time period is limited.2 It is therefore clear that additional 
modalities for imaging PCa (such as PET) should be considered. 
1.4 Fluorine-18 Positron Emission Tomography 
PET is a three-dimensional nuclear medicine imaging technique that can observe 
functional processes occurring in the body by detecting γ rays indirectly resulting from 
the decay of specific radioisotopes.2, 5 These radioisotopes include (amongst others): 18F 
(t1/2 = 109.8 mins), 64Cu (t1/2 = 12.7 hrs), 68Ga (t1/2 = 67.8 mins) and 11C (t1/2 = 20.3 
mins).2, 4 Positron (β+) emission occurs when one of the above nuclei starts to decay 
owing to the presence of a surplus of protons, which have the effect of destabilizing the 
nucleus.2 In order to gain stability, the nucleus of the atom converts a proton into a 
neutron, a positron and a neutrino.2 In the case of fluorine-18, this results in the formation 
of the stable oxygen-18 isotope and the release of the positron and neutrino.2 This process 
is shown below (Figure 2). The positron, being highly unstable, quickly loses kinetic 
energy and decelerates before annihilating with an electron from the nuclei of 
surrounding tissue.2 This event causes the release of two 511 keV photons at 180° to each 
other, which are picked up by a series of rings on the PET detector.2 The consequent 
electrical signals are transformed into sinograms that make up the tomographic image 
after a number of processing steps (Figure 2).2 The images acquired from PET have a 
clinical spatial and temporal resolution of 5-7 mm and seconds-minutes respectively.2 
This is only slightly worse than CT, where a spatial resolution of 0.5-1 mm and temporal 
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resolution of minutes is obtained in the clinic.2 In addition, PET possesses a high level of 
sensitivity (10-11 – 10-12 M) allowing low radiotracer concentrations to be detected.2  
 
e+


Annihilation
511 keV
511 keV
Detection
Detection
Image Reconstruction
 
Figure 2. Positron emission and the principle of PET imaging. 
The most commonly used clinical imaging probe for the identification, staging and 
monitoring of carcinoma is [18F]FDG (Figure 3a). First synthesized by Ido and co-
workers,20 this radioactive glucose derivative is injected into the body intravenously.2  
 
 
 
 
 
 
Figure 3. a) Structure of [18F]FDG b) whole body human PET scan using [18F]FDG.21 
O
HO
HO OH
OH
18F
a
b
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Due to the fact that cancer cells have a higher rate of glucose metabolism than normal 
cells (known as the Warburg effect22), radiotracer accumulation differs between both cell 
types, ultimately leading to a difference in contrast in the PET image.5 A representative 
PET image is shown on the previous page (Figure 3b). 
Unfortunately, much as in the case of MRI and CT, a number of limitations exist, 
especially with respect to the imaging of prostate cancer. In spite of the fact that a 
combination of PET/CT using the radiotracer [18F]FDG enables tumour localization via 
the Warburg effect,22, 23 the probe suffers from renal excretion, thus masking possible 
prostatic tumours due to the build-up of activity in the bladder.18, 24 In addition to this, 
PET has a limited ability to distinguish between benign and malignant disease, in spite of 
the use of alternative radiotracers such as [18F]fluorodihydrotestosterone (FDHT, 
molecule 1)18, [11C]acetate (2),25 [18F]Choline, (3)18 and [11C]methionine (4).18, 26 It is 
therefore clear that the development of novel PET imaging agents to improve 
differentiation between benign and malignant prostatic tumours (as well as addressing the 
clinical issue of over-diagnosing prostate cancer and thus over-treating potentially benign 
tumours) is of paramount importance.6      
 
Figure 4. Examples of clinically used PET imaging agents for diagnosing prostate 
cancer.18 
1.5 Peptide-based Imaging Agents 
Molecular imaging agents generally consist of two parts: a targeting entity and a 
signalling entity (Figure 5, overleaf). The former component ensures that the imaging 
probe interacts effectively with the desired target. In the specific case of a peptide-based 
imaging agent binding to a G-protein coupled receptor, this represents the probe’s 
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pharmacophore. On the other hand, the signalling entity allows the target to be detected 
by the imaging modality being used. For peptides that are to be detected through PET, 
this entity is formed via insertion of a positron-emitting radionuclide into the structure of 
the peptide. This can occur by using a chelator, which is often separated from the peptide 
by a linker (e.g. polyethylene glycol, PEG), so as to prevent interference between the 
respective entities.2 This approach is mainly used for radiometals such as 68Ga and 
64Cu.27 Common chelators include 1,4,7,10-tetraazadodecane-N,N’,N’’,N’’’-tetraacetic acid 
(DOTA)28 for 68Ga and cross-bridged-tetraazamacrocycle 4,11-bis(carboxymethyl)-
1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A)29 for 64Cu. On the other hand, the 
radioisotope 18F is introduced into peptides without the use of a chelator. Small molecules 
such as N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB)30 and 4-[18F]-fluorobenzoic 
acid ([18F]FBA)31 are predominantly used. This is because adding the 18F radioisotope 
directly into the main peptide sequence is frequently difficult to perform and not 
sufficiently regio-selective. Instead, addition of a pre-formed 18F-radiolabelled small 
molecule (known as a “prosthetic group”)32 is more convenient. However, direct routes 
for 18F radioisotope insertion into peptides using fluorine-19 chemistry do exist.2, 33, 34  
 
 
 
Figure 5. The general design of an imaging agent. 
Once the imaging agent has been synthesized, it is tested and modified so as to establish 
the following favourable attributes (step 5 of the molecular imaging study described in 
Figure 1): high target selectivity, good in vivo stability, low toxicity, decreased non-
specific binding, signal amplification and multiplexing potential.2  
Peptides are a very versatile class of imaging agents that possess a variety of 
advantageous properties: facile synthesis by solid-phase peptide synthesis (SPPS), fast 
clearance from the body and a high degree of selectivity and specificity.2, 35 They also 
possess flexibility in terms of the type of changes that can be introduced without 
 Targeting Entity  
Signalling  
   Entity 
Linker 
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significantly affecting the binding affinity.2, 35 In addition, despite their lower binding 
affinity compared to antibodies, they have a greater level of in vivo stability and lower 
likelihood of eliciting an immune response.2, 36 These factors play a large part in the 
frequent use of peptides as imaging entities.   
A number of recent studies aiming to image prostatic tumours utilize peptide-based 
imaging agents. For example, Y. Liu et al.,27 recently synthesized several radiolabelled 
bombesin analogues that targeted the gastrin-releasing peptide receptor (GRPr), which is 
known to be overexpressed in PCa.27, 37 Amongst the synthesized compounds, two of the 
imaging agents were 64Cu-chelated-peptides, namely 64Cu-1,4,7-triazacyclononane,1-
glutaric acid-4,7 acetic acid-DOTA-CH2CO-G-4-aminobenzoyl-QWAVGHLM-NH2 
(64Cu-NODAGA-AMBA) and 64Cu-NODAGA-DOTA-CH2CO-G-4-aminobenzoyl-
fWAVGH-Sta-L-NH2 (64Cu-NODAGA-RM1).27  These compounds were used to image 
PC3 tumours in mice.27 Both imaging probes exhibited good tumour-to-background 
ratios, with 64Cu-NODAGA-RM1 showing persistent tumour uptake four hours post-
injection.27  
An alternative non-radiolabelled approach was taken by the work of Lu and co-workers.6 
This involved fluorescent imaging of the growth hormone secretagogue receptor 1a 
(GHS-R1a),6 which is known to be expressed in a number of prostate cancer cell lines 
such as ALVA-41, LNCaP, DU145 and PC3.38 It was found that this receptor had a 
differential expression in normal, benign and cancerous prostatic tissue.6 This was 
indicated by the specificity of the peptidic imaging probe fluorescein-ghrelin(1–19) 
towards PCa, with low level association in BPH, prostate intraepithelial neoplasia (PIN) 
and normal prostatic tissue6 (compound 5, Figure 6). By moving from the original 
peptide based fluorescein-ghrelin(1-19) to peptidomimetics, imaging agents with superior 
targeting, stability and pharmacokinetic properties should result. In addition, by using 
PET as the primary imaging modality over fluorescent imaging, a more clinically 
translatable imaging probe would result. 
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Figure 6. Structure of the fluorescein ghrelin(1-19) imaging probe. 
1.6 Scope of Thesis 
This thesis deals with the synthesis of a variety of peptidomimetic growth hormone 
secretagogue (GHS) agonists targeting the GHS-R1a, known to have a differential 
expression in normal, benign and malignant prostatic tissues.6 To begin with, an 
introduction is given to the field of GHSs, encompassing their initial development and 
use as a means to treat growth hormone deficiency (section 2.1). This is followed by a 
short discussion on the preference for an agonist imaging agent over an antagonist 
imaging probe. A number of reasons are then given for the peptidomimetic structures 
employed by the agonists in section 2.3, with a detailed account on the available literature 
that covers their interaction with the GHS-R1a. Section 2.4 deals with the strategy for 
modifying the peptidomimetic agonists for 18F radioisotope introduction by synthesizing 
a series of 19F mimics with the 4-[19F]fluorobenzoic acid (4-[19F]FBA) prosthetic group. 
The results and discussion begins by describing the synthesis of these 19F-fluorobenzoyl 
peptidomimetic GHS-R1a agonists and their characterization by high-performance liquid 
chromatography (HPLC), high-resolution mass spectrometry (HRMS) and proton-nuclear 
magnetic resonance spectroscopy (1H-NMR). Furthermore, a description of the biological 
evaluation of these 19F-mimics through competitive in vitro receptor-ligand binding 
assays using human embryonic kidney 293 cells stably transfected with the GHS-R1a 
receptor (HEK293/GHS-R1a) and [125I]ghrelin as the radio-ligand follows. This led to the 
identification of the lead compound [1-Nal4,Lys5(4-FB)]G-7039. The results of the 4-
fluorobenzoyl (4-FB) modifications and their effect on the receptor binding affinity are 
examined. Partition coefficients are calculated for the 19F-fluorobenzoyl agonists using 
ACD/logP and XLOGP3 software and discussed. A calcium flux assay was used to check 
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the retention of agonist activity for [1-Nal4,Lys5(4-FB)]G-7039. Finally, 18F-
radiolabelling of the lead compound’s parent precursor [1-Nal4]G-7039 using [18F]FBA 
and [18F]SFB is elaborated upon. A conclusions section completes this approach.   
The next section (2.5) looks briefly at an alternative way of modifying the agonists with a 
racemic 2-fluoropropionyl (2-FP) group and the results from that endeavour. This section 
covers a discussion of the computationally calculated LogP values of the 2-FP 
peptidomimetic GHS-R1a agonists, a series of receptor binding assays and a calcium flux 
assay. A discussion of possible 18F-radiolabelling strategies for the lead compound 
[Lys5(2-FP)]G-7039 identified by the binding assays (as well as a conclusions section) 
completes the chapter. The entire body of the work described above is concentrated into 
Chapter 2. This project was carried out in collaboration with Dr. Savita Dhanvantari, an 
Assistant Professor in Medical Biophysics at the University of Western Ontario and a 
Scientist at the Lawson Health Research Institute, London, Ontario, Canada. 
Chapter 3 reviews the findings of Chapter 2 and looks at the future direction of prostate 
cancer imaging with PET.  
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Chapter 2  
The Design and Synthesis of Peptidomimetic GHS-R1a 
Agonists as PET Imaging Agents for Prostate Cancer 
2.1 Introduction 
In 1977, Bowers and co-workers were studying enkephalin (EK) analogues (Figure 7, 
compounds 6 and 7) in order to gain a better understanding of small peptide structure-
activity relationships related to pituitary hormone secretion.39 During the course of their 
research they found that certain enkephalin derivatives (such as DTrp2-Met-EK-NH2 for 
example) released growth hormone (GH) in vitro from the pituitary glands of female 
rats.39 This eventually led them to discover the hexamer H-His-D-Trp-Ala-Trp-D-Phe-
Lys-NH2 in 1984, which represented the first synthetic peptide that released GH in vitro 
in rats and in vivo in a number of animals including lambs, rats, monkeys40 and humans.41 
This compound was later termed growth hormone releasing peptide 6 (GHRP-6, 
compound 8). In 1989, a paper by Ilson et al42 discussed the potential of these synthetic 
peptides to replace recombinant human growth hormone (rhGH) for the treatment of GH 
deficiency.42 This form of therapy is expensive and requires injection or inhalation of the 
recombinant hormone on a daily basis.43  
 
Figure 7. Enkephalin analogues and the most widely studied GHRPs. 
Following the publication of this paper, interest in the field of growth hormone releasing 
peptides began to grow. Two second generation derivatives of GHRP-6 were synthesized 
in 1993, GHRP-144 and KP-102 (later termed GHRP-2)41, 45 (compounds 9 and 10 
respectively). These peptides were also found to release GH in vivo in humans.41 Growth 
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hormone releasing peptides belong to a class of compounds known as growth hormone 
secretagogues.46 These are compounds that are specifically defined as molecules that 
stimulate the secretion of pituitary GH through a route different from that of GH 
releasing hormone (GHRH).46 Between 1993 and 1995 a number of GHSs were 
synthesized by research teams with the aim of developing orally bioavailable drugs for 
treating GH deficiency. These included small molecules such as L-692429, L-692585 and 
MK-0677 (all Merck & Co.),47-49 EP-51389 (Europeptides),50 peptides such as hexarelin 
(Mediolanum Farmaceutici)51 and peptidomimetics such as G-7039, G-7143, G-7203 and 
G-7502 (all Genentech).52 
In 1996 the group of R. Smith at the Merck Sharp & Dohme Research Laboratory (USA) 
identified the receptor that these compounds acted on through expression cloning 
methods.53-55 This receptor belongs to the GPCR family56 and constitutes seven 
transmembrane (TM) regions, 366 amino acids and has an approximate mass of 41 
kDa.54, 55 It was termed the GHS-R1a in order to distinguish it from its splice variant, the 
GHS-R1b, a five TM, 289 amino acid protein with unknown biological activity.54, 55 A 
schematic diagram of the predicted GHS-R1a topology is shown in Figure 8.   
 
Figure 8. Schematic diagram of human GHS-R1a topology. 
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The GHS-R1a is predominantly expressed in the hypothalamus and pituitary, as well as 
in the thyroid gland, stomach, intestine, pancreas, spleen, ventricular myocardium, aorta, 
lung, adrenal gland, kidney, adipose tissue, testis, ovary and lymphocytes.55  
Three years later, the endogenous ligand for the GHS-R1a was isolated from the rat 
stomach by Kojima and co-workers,57 thereby completing the cycle of reverse 
pharmacology. This ligand, termed “ghrelin” (compound 11, Scheme 1) is a 28 amino 
acid peptide with an n-octanoyl group on the Ser 3 side-chain that is important for 
binding to the GHS-R1a and releasing GH in vivo.57 In addition, this acylation is also 
responsible for ghrelin’s numerous biological activities, such as regulation of glucose 
metabolism,58 insulin release,59 gut motility,60 and many others.55 
 
Scheme 1. Truncated ghrelin derivatives (Merck). 
Following the isolation of ghrelin, research shifted towards truncated ghrelin derivatives. 
This was carried out in order to identify the active pharmacophore of the peptide that is 
responsible for its biological activity.61 Amongst these derivatives are peptide agonists 
12-14 developed by Merck (Scheme 1). Scientists at Merck found that only the first four 
to five N-terminal amino acids of ghrelin (Gly-Ser-Ser-Phe/-Leu) were needed to bind to 
and activate the receptor.61 This is clearly indicated by the decrease in in vitro potency 
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(half-maximal effective concentration, EC50) with decreasing number of N-terminal 
residues (Scheme 1, cf. 12 to 13 to 14, EC50 = 11.5 ± 2.3 nM, 72 ± 29 nM and >10,000 
nM respectively).61   
Unfortunately, these shortened ghrelin derivatives were incapable of releasing GH in 
vivo.62 This could be due to lower expression levels of the ghrelin receptor in pituitary 
cells compared to its overexpression in the HEK293 cells used to determine the EC50 
values mentioned above.62 Up to the present day, a wide range of GH secretagogues have 
been synthesized since the discovery of ghrelin. These encompass (but are certainly not 
limited to) small molecules developed by Merck,63 Bristol-Myers Squibb,64 Sumitomo 
Pharmaceuticals65 and Abbott Laboratories66 as well as the extensive work on 
peptidomimetic and pseudo-peptide agonists at Novo Nordisk (DK), whose structures 
possess some pharmacophoric similarities to the native ligand ghrelin.67-77   
The development of an imaging probe targeting the ghrelin receptor based on the 
extensive research in the area of GHSs involves three main steps. Firstly, the nature of 
the ligand is decided upon. This can be divided up into two possible candidates: an 
agonist or an antagonist. Secondly, the structural nature of the ligand is established, with 
peptidomimetic, peptide or small molecule frameworks to choose from. Finally, the 
location and method of radioisotope incorporation into the structure of the imaging agent 
is determined. The following sub-sections (2.2-2.4) address these respective challenges 
and explain the rationale behind the design and synthesis of the peptidomimetic GHS-
R1a agonists found in this chapter.  
2.2 Agonists and Antagonists in Molecular Imaging 
From a historical standpoint, agonists have been most frequently used as radiolabelled 
peptides aimed at imaging peptide receptors overexpressed in cancerous tumours.4 The 
most well-known example of this are the somatostatin receptors which have been known 
to be up-regulated in a variety of neuroendocrine tumours since the 1980s.78, 79 In this 
form of oncological imaging, a radiolabelled somatostatin derivative (e.g. 111In-
OctreoScan4) is intravenously injected into the subject under study, where it will 
specifically target the highly expressed somatostatin receptors in the plasma membranes 
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of the cells that make up the neuroendocrine tumours.78 As the somatostatin analogue is 
an agonist, a receptor-radioligand complex forms upon agonist binding.80 This complex is 
then internalised into the tumour cell, which results in an increase in the amount of 
radioactivity in the tumour in comparison to other organs.78 As a consequence of this 
accumulation of radioactivity, an increase in contrast and thus in vivo target visualization 
by PET results.4, 78 The ability to internalize with the receptor is believed to make 
radiolabelled peptide agonists better adapted to targeting tumours compared to 
antagonists.4 This is because receptor-ligand internalisation is not possible for antagonists 
(despite typically having a higher binding affinity than agonists80) as they do not activate 
the receptor, but rather, prevent the natural ligand or agonist from interacting with it.4 
This is the primary reason for choosing an agonist over an antagonist in the design of 
PET imaging agents targeting the GHS-R1a in PCa. 
However, it should be noted that the development of antagonist imaging probes for 
cancer imaging is currently a heavily researched topic in the field of radiolabelled peptide 
imaging probes.28, 29, 81 A recent paper by Wieser et al.,29 has shown that clinical imaging 
of prostate cancer using the radiolabelled GRPr antagonist 64Cu-4,11-
bis(carboxymethyl)-1,4,8,11-tetraazabicyclo(6.6.2)hexadecane-PEG4-D-Phe-Gln-Trp-
Ala-Val-Gly-His-Sta-Leu-NH2 (64Cu-CB-TE2A-AR06) resulted in reduced kidney and 
intestine uptake with a higher tumour uptake when compared to GRPr agonists.29 The 
mechanism of action of the antagonist or the reasons behind these results is not currently 
known. The preference for an antagonist radiotracer does not seem to be isolated to the 
GRPr receptor however.29, 81 
2.3 Design of Agonist and Structure Activity Relationships 
The decision to use peptidomimetic agonists rather than a single class of small molecule 
GHS-R1a agonists was based on a number of reasons. Firstly, peptidomimetic agonists 
tend to have a peptide-based structure that allows for facile and rapid synthesis using 
manual or automated fluorenylmethyloxycarbonyl SPPS (Fmoc-SPPS). This is in contrast 
to small molecules, where synthetic procedures can be somewhat lengthy. Secondly, 
given the fact that small molecule agonists mostly consist of the pharmacophore required 
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to interact with the receptor, addition of a radioisotope for imaging would likely have a 
greater effect on this pharmacophore compared to a peptide, where the pharmacophore 
typically forms part of the structure with the non-pharmacophoric portion acting as a 
supporting framework. In addition, the process of screening existing GHSs to find new 
small molecule “hits” would likely be a tedious and time-consuming enterprise. Most 
importantly of all, the wealth of previous research on GHRPs, pseudo-peptide and 
peptidomimetic GHSs as well as their interaction with the ghrelin receptor gives clues as 
to the kind of structural modifications that may be required to develop them into imaging 
agents. Such structure-activity relationships form the starting point for the design of 
peptidomimetic agonists targeting the ghrelin receptor.82-87 
The first such study was carried out by Feighner et al.,82 who used site-directed 
mutagenesis88 and molecular modelling to determine the key residues required by the 
ghrelin receptor in order to be activated by peptide (GHRP-6, compound 8) and non-
peptide (MK-0677, 15 and L-692585, 16) agonists (Figure 9).82  
 
Figure 9. Growth hormone secretagogues used in Feighner et al’s study. 
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This activation was assessed via an aequorin bioluminescence assay, where the degree of 
aequorin photoprotein luminescence (caused by intracellular calcium ions) indicated the 
extent of GHS-R1a activation.82 Using homology modelling89 founded on the helical 
impression of bacteriorhodopsin as well as a two-dimensional sequence alignment of 
repeated motifs in a number of associated GPCRs (specifically the neurotensin, 
somatostation-2, angiotensin II and β2-adrenergic receptors as well as human, swine and 
rat GHS-Rs) the importance of a number of amino acids required for successful ligand 
interaction was predicted.82 These results were then confirmed through mutagenesis 
studies on those residues. Figure 10 shows the 366 amino acids of ghrelin receptor along 
with its predicted topology (the phospholipid bilayer has been omitted for clarity). 
Mutated residues are highlighted in red. 
 
Figure 10. Amino acid sequence of the ghrelin receptor and residues identified for 
mutation in Feighner et al’s study. 
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By far the most significant residue for receptor activation was found to be the E124 
residue in transmembrane region 3 (TM3), which is believed to form a salt bridge with 
the primary ammonium cation in the N-terminus of the peptide ligand, or the amino 
group present in both small molecules.82 This non-covalent interaction was initially 
observed in a docking model of L-629585 with the ghrelin receptor,90 postulated to be 
similar to the ligand-binding interaction of the D113 residue in the β2-adrenergic 
receptor91 and finally confirmed through replacement of E124 with Q124, which 
deactivated the GPCR.82 The M213 residue was shown to be crucial for binding L-
692585.82 In addition, mutation of the D99 residue (TM2) to N99 resulted in a more than 
two fold reduction in the functional activity of the receptor.82 The mutation of C116 
(TM3) to A116 was found to destroy all agonist activity, as the thiol group is believed to 
form a disulfide bond with the agonists, an interaction that is retained in all GPCRs.82, 92 
Finally, a decrease in the binding of [35S]-MK-0677 to GHS-R1a was observed upon 
mutation of S123 to A123 and Q120 to H120 in TM3 (dissociation constant: KD = 0.27 
nM for wild-type ghrelin and KD = 0.12 nM for both mutants respectively) thereby 
highlighting the importance of these residues for ligand interaction.82 
A second SAR study was performed by Huang and co-workers in 2001.83 This involved 
the identification of pharmacophoric regions (A-F) in six peptidyl- and four non-peptidyl 
agonists of the ghrelin receptor. Using these regions, an in-house computer program 
(DistComp)93 determined a 3D pharmacophore common to all agonists with the inactive 
congener [Val3]GHRP-6 used as a negative control.83 This calculation was achieved by 
inputting a library of low-energy conformers for each compound into the DistComp 
software.83 The three-dimensional pharmacophore represented the ensemble of functional 
groups necessary for successful activation of the G-protein coupled receptor and is shown 
in Figure 11 overleaf.83 
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Figure 11. GH secretagogue 3D pharmacophore established by DistComp. 
Having derived the pharmacophore, it was screened against a large database of 
compounds in order to find potential “hits” where the ensemble of moieties matched 
those of the pharmacophore in similar regions of space.83 After the discovery of an initial 
lead compound, further optimization was carried out using a site-dependent fragment 
QSAR program.83 This resulted in the synthesis of a benzothiazepin GH secretagogue 17 
which was found to have low nanomolar efficacy, thereby proving the validity of both 
computational techniques (Figure 12).83 
 
Figure 12. Benzothiazepin compound with nanomolar in vitro potency. 
The 3D pharmacophore confirmed the importance of the protonable amine (identified in 
the site-directed mutagenesis study by Feighner et al),82 and also established the necessity 
for a core framework of aromatic amino acids and an amidated C-terminal, the latter of 
which also lends in vivo stability to peptide-based GHS-R1a agonists.83 In addition, some 
of these computational findings supported the experimental work of Hansen and co-
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workers69 who discovered that aromatic amino acids and a C-terminal amide play an 
important role in binding to the receptor for tripeptide derivatives of the compound 
ipamorelin.69  
A second computational study was performed by Pedretti and co-workers,84 who decided 
to construct a full-length model of the human ghrelin receptor in its open state through 
the use of a fragmental prediction strategy.84 The first step divided up the primary 
structure of the transmembrane protein into a series of 15 fragments which then 
underwent homology modelling. The final receptor model was then constructed by 
overlaying each fragment backbone onto the corresponding fragment in the structure of 
rhodopsin.84 Docking of the receptor with the active core of ghrelin Gly-Ser-Ser(n-
octanoyl)-Phe-NH2 and 35 literature peptidomimetic GH secretagogues was used to 
validate the model.84 The results substantiated the existence of two separate sub-pockets 
located in the binding domain of the ghrelin receptor: a polar sub-pocket bordered by 
TM2 and TM3 and a non-polar/aromatic sub-pocket lined by TM5 and TM6.84 These 
binding pockets are located far enough apart from each other that a ligand cannot interact 
with both concurrently.84 However, the outcome of docking studies was that some of the 
most active nanomolar compounds were capable of interacting strongly with either sub-
pocket, implying that there may be a co-operative effect between both binding modes.84 It 
was thought that the binding of GHSs to the aromatic sub-pocket could be transitioning 
the receptor into an inherently active state via a non-competitive mechanism of partial 
agonism.84 The overall GH-releasing effect could therefore be taken as a combination of 
full agonism in the polar cavity and partial agonism in the non-polar cavity.84 A follow up 
paper by the same authors on the GHS-R1a suggested that GH secretagogues could also 
bind to the inactive closed state, although it was unclear whether ligands could 
distinguish this from the open state.85 
Experimental studies examining the interaction of ghrelin with the ghrelin receptor are 
also useful in determining important pharmacophoric parameters for strong receptor 
binding. Amongst these, the work of Martín-Pastor et al.,86 and Jӧrg Groβauer and co-
workers87 are the most notable. In the former paper, a 1H-NMR study was conducted on 
the interaction of ghrelin and its un-acylated analogue des-acyl ghrelin with stably 
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transfected HEK293/GHS-R1a and Chinese hamster ovary (CHO)/GHS-R1a cell lines in 
phosphate-buffered saline (PBS).86 A change in the chemical shift of aliphatic protons on 
the n-octanoyl side-chain was observed in the 1H-NMR spectrum of ghrelin.86 Further 
experiments using two dimensional total correlation spectroscopy (2D TOCSY) 
examining chemical shift perturbations (CSP) and slow conformational exchange (SCE) 
effects showed that a considerable number of residues were affected by the interaction of 
ghrelin with the GHS-R1a receptor, including the n-octanoyl group.86 This suggests that 
there is a significant change in the conformation of the peptide when it interacts with the 
receptor.86 The absence of CSP and SCE effects for des-acyl ghrelin confirmed the 
importance of the n-octanoyl group in binding to the receptor and supports the evidence 
that this moiety is responsible for ghrelin’s biological activity.57, 86 
On the other hand, the latter paper utilized dodecyl-phosphocholine (DPC) micelles as 
membrane-mimetics for the GHS-R1a to study the residues of ghrelin involved in 
receptor binding based on changes in chemical shift and paramagnetic relaxation 
enhancements (PRE) in 1H-NMR spectra.87 It was found that ghrelin binds to the micelles 
through its Ser3 n-octanoyl side-chain. This is further strengthened by hydrophobic 
interactions from the side-chain of Phe4.87 Low PRE values observed for the n-octanoyl 
group indicated deep immersion in the micellar membrane suggesting that it may also 
behave as a membrane anchor87 (a role observed with myristoyl and palmitoyl 
functionalities94). This paper corroborates the results of Bednarek et al61 who showed that 
the first 4-5 residues of ghrelin were critical for its activity and also the results from the 
1H-NMR study of Martín-Pastor and co-workers86 regarding the importance of the n-
octanoyl group. 
2.4 Initial 18F-Radiolabelling Strategy  
The SAR studies covered in section 2.3 not only identified the classes of functional 
groups (small molecules) and amino acids (peptidomimetics) that were required by 
compounds to bind strongly to the ghrelin receptor, but also shed some light onto the 
types of amino acid residues that are open to modification.82-87 Out of the peptidomimetic 
GHS-R1a agonists found in the literature, the most promising amino acid for 
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modification appeared to be lysine, located at the C-terminus. This was because it did not 
appear to exhibit pharmacophoric importance in any of the pertinent experimental82 and 
computational83 studies discussed in section 2.3. This residue is common to the most 
well-known GHRPs (GHRP-6, GHRP-2, GHRP-1) as well as ipamorelin (Novo Nordisk) 
and G-7039 (Genentech). As a direct consequence of this, the amino group of the lysine 
side-chain was targeted as the location for 18F-radioisotope insertion in the above 
molecules. 
Fluorine-18 is a β+ emitter5 that is frequently used in positron emission tomography, an 
imaging modality that was covered extensively in chapter 1. This radioisotope was 
chosen preferentially for insertion into the peptidomimetic agonists over a number of 
other radioisotopes used in nuclear medicine such as 68Ga, 11C and 64Cu. This is because 
it is a small innocuous unit that can be incorporated into the agonist structure without 
significantly affecting receptor binding affinity. In contrast, 68Ga or 64Cu both require a 
large bulky chelator95, 96 which is impractical for small peptide-based agonists. Further, 
18F has a half-life of 109.8 minutes5 which provides a good time window for carrying out 
imaging (cf. 11C whose half-life is only 20.3 minutes23). Furthermore, this shorter half-life 
reduces the radioactive dose experienced by the patient in the clinic. 
The initial strategy for 18F radioisotope insertion into the lysine side-chain of the 
peptidomimetic agonists was based on common literature acylation methods of amino 
groups using either [18F]FBA97 or [18F]SFB98-100 prosthetic groups. However, prior to 
incorporation of the radioisotope, it is important to test this modification in order to 
determine whether a significant change in agonist receptor binding would result. This 
was performed by utilizing 4-[19F]FBA, a “cold” non-radioactive prosthetic group mimic 
which was coupled to the lysine side-chain of the peptidomimetics by standard Fmoc-
SPPS methodology. The principle aim of this strategy was to acquire a compound with a 
binding affinity of < 100 nM, owing to the low density of the GHS-R1a in prostate cancer 
tumours.6 The technique of Fmoc-SPPS, along with the synthetic scheme and the 
obtained characterization data of the purified peptidomimetic GHS-R1a agonists is 
discussed in section 2.4.1 below. 
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2.4.1 Results and Discussion 
2.4.1.1 Synthesis of 4-FB Peptidomimetic GHS-R1a Agonists 
The ghrelin receptor agonists were synthesized by standard Fmoc-SPPS manually or by 
using the Biotage® Syro Wave™ automated peptide synthesizer. The general procedure 
for this process is shown in Scheme 2 below. 
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Scheme 2. General procedure for manual Fmoc-SPPS. Reagents and Conditions: a) 20% 
piperidine/DMF b) i) Fmoc-amino acid, HCTU, DMF ii) DIPEA c) 95% TFA: 2.5% 
H2O: 2.5% TIPS (5-7 hours). 
Briefly, the N-protecting Fmoc group on the rink amide resin 18 was deprotected with a 
solution of 20% piperidine in dimethylformamide (DMF). Coupling of the Fmoc-amino 
acid to the free amine 19 was performed in DMF using the coupling reagent 2-(6-chloro-
1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) in the 
presence of diisopropylethylamine (DIPEA). This resulted in the formation of peptide 20. 
The coupling step was typically carried out for a period of one hour. The successful 
completion of this reaction was assessed either through a micro-cleave or thorough the 
qualitative Kaiser test101 (see experimental section 4.2.3). After the coupling step, the 
resin was washed a number of times with DMF before the next cycle of coupling was 
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initiated (20 to 21). Once all of the desired amino acids had been reacted, a final removal 
of the N-terminal Fmoc group was performed, leading to peptide 22 with a free N-
terminal amine. This peptide was then cleaved from the resin using a solution of 95% 
trifluoroacetic acid (TFA): 2.5% H2O: 2.5% triisopropylsilane (TIPS) for 5-7 hours. The 
crude peptide 23 was purified by preparative HPLC. The full procedure for manual 
Fmoc-SPPS can be found in experimental section 4.2.1. 
The 4-[19F]FBA moiety was introduced into the peptidomimetic agonists by way of the 
orthogonal allyloxycarbonyl (Alloc) protecting group present on the amino group of the 
lysine side-chain (Scheme 3). 
 
Scheme 3. Orthogonal protecting group strategy and coupling of 4-[19F]FBA illustrated 
for the peptide ipamorelin. 
Using palladium chemistry, the Alloc protecting group was selectively removed from 
peptide 24 with Pd(PPh3)4 in the presence of the PhSiH3 allyl group scavenger.102-105 This 
resulted in the formation of compound 25 with a free amine. Amino acid coupling 
employing the conditions described previously delivered the final fluorobenzoylated 
peptide 4-FB-ipamorelin, 26. By making use of both procedures outlined in the schemes 
above, 17 peptidomimetic GHS-R1a agonists were synthesized. The names, compound 
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identification numbers (LCE numbers) and amino acid sequences of the peptidomimetics 
are shown in Table 1 below. 
Peptidomimetic LCE number 
Amino Acid Sequence 
Ipamorelin 00210 H-Aib-His-D-2-Nal-D-Phe-Lys-NH2 
[Lys5(4-FB)]ipamorelin 00211 H-Aib-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 
[Lys5(AEEA-4-
FB)]ipamorelin 
00217 H-Aib-His-D-2-Nal-D-Phe-Lys(AEEA-4-FB)-
NH2 
GHRP-6 00239 H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 
GHRP-1 00240 H-Ala-His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 
[Lys5(4-FB)]G-7039 00243 H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(4-FB)-NH2 
[1-Nal4]G-7039 00244 H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2 
G-7039 00245 H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2 
[Inp1,D-2-Thi4,Lys5(4-
FB)]ipamorelin 
00246 H-Inp-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 
[D-2-Thi4,Lys5(4-
FB)]ipamorelin 
00267 H-Aib-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 
[Inp1,Lys5(4-FB)]ipamorelin 00268 H-Inp-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 
[Inp1,D-2-Nal4,Lys5(4-
FB)]ipamorelin 
00269 H-Inp-His-D-2-Nal-D-2-Nal-Lys(4-FB)-NH2 
[1-Nal4,Lys5(4-FB)]G-7039 00270 H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(4-FB)-NH2 
[Lys6(4-FB)]GHRP-6 00272 H-His-D-Trp-Ala-Trp-D-Phe-Lys(4-FB)-NH2 
[Dpr6(4-FB)]GHRP-6 00281 H-His-D-Trp-Ala-Trp-D-Phe-Dpr(4-FB)-NH2 
GHRP-2 00282 H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 
[Dpr6]GHRP-6 00298 H-His-D-Trp-Ala-Trp-D-Phe-Dpr-NH2 
Table 1. Synthesized peptidomimetics and their amino acid sequences. 
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All final compounds were characterized by HPLC, 1H-NMR and HRMS (ESI-TOF). The 
HRMS data, along with the % yields and purities are shown for the peptidomimetic 
agonists below (Table 2). All compounds were acquired with purities > 95% by HPLC 
and with HRMS data within acceptable error to computed values (± 0.003 amu). 
LCE number HRMS (calculated) 
[M + H]+ 
HRMS (found) 
[M + H]+ 
% 
Purity 
% 
Yield 
00210 712.3935 712.3959 > 97 19 
00211 834.4103 834.4133 > 99 15 
00217 979.4842 979.4868 > 98 8 
00239 873.4524 873.4531 > 97 14 
00240 955.4943 955.4964 > 99 19 
00243 920.4511 920.4529 > 97 6 
00244 848.4499 848.4501 > 99 23 
00245 798.4343 798.4339 > 99 7 
00246 866.3824 866.3850 > 99 13 
00267 840.3667 840.3693 > 98 4 
00268 860.4259 860.4284 > 96 6 
00269 910.4416 910.4400 > 98 10 
00270 970.4667 970.4693 > 96 9 
00272 1017.4511 [M + Na]+ 1017.4522 [M + Na]+ > 96 7 
00281 953.4223 [M + H]+ 953.4237 [M + H]+ > 98 14 
00282 840.4204 [M + Na]+ 840.4173 [M + Na]+ > 99 17 
00298 831.4055 [M + H]+ 831.4070 [M + H]+ > 99 3 
Table 2. Yields, purities and HRMS data for the synthesized GHS-R1a agonists. 
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Having synthesized the 4-FB peptidomimetic agonists, competitive radioligand binding 
assays on HEK293/GHS-R1a cells with [125I]ghrelin were used to assess the binding 
affinities of the peptidomimetics for the ghrelin receptor in terms of the half-maximal 
inhibitory concentration. The IC50 value is defined as the concentration of the agonist that 
prevents 50% of the radioactive ligand from being bound to the receptor80 (in this case 
[125I]-ghrelin). It is therefore an indicator of the relative binding strength of the agonist 
for the receptor binding site.  
2.4.1.2 4-FB Agonist Receptor-Ligand Binding Assays 
Before testing any novel peptidomimetics containing the 4-FB group, the endogenous 
ligand for the GHS-R1a (ghrelin) was tested in the receptor-ligand binding assay. This 
behaved as a positive control that showed whether successful overexpression of the 
receptor in the HEK293 cells had been achieved. The curve for ghrelin is shown in Figure 
13. The obtained IC50 value of 7.63 nM is consistent with previous values obtained within 
our group, indicating that GHS-R1a expression is at a satisfactory level and initial 
compound testing may proceed.  
 
Figure 13. Representative IC50 curve for the endogenous ligand ghrelin. 
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The starting peptidomimetic compound that was chosen for 19F-fluorobenzoylation was 
the pentapeptide ipamorelin (H-Aib-His-D-2-Nal-D-Phe-Lys-NH2). This compound was 
first synthesized by K. Raun and co-workers at the Novo Nordisk A/S research facilities 
in Denmark.67 Derived from GHRP-1,44 ipamorelin displayed a low nanomolar binding 
affinity (Ki) in a previously reported study using HEK293 cells stably transfected with 
the GHS-R1a (Ki = 240 nM).106 It was postulated that introduction of a fluorobenzoyl 
moiety into the structure of ipamorelin at the lysine side-chain should not significantly 
affect binding to the receptor, due to the absence of this R group as a pharmacophoric site 
in Huang et al’s study.83 The IC50 value for this modification can be found in Table 3 
(LCE00211).  
LCE no. Compound Name IC50, nM 
00210 Ipamorelin 483 
00211 [Lys5(4-FB)]ipamorelin 170 
00217 [Lys5(AEEA-4-FB)]ipamorelin 474 
00246 [Inp1,D-2-Thi4,Lys5(4-FB)]ipamorelin 1170 
00267 [D-2-Thi4,Lys5(4-FB)]ipamorelin 161 
00268 [Inp1,Lys5(4-FB)]ipamorelin 688 
00269 [Inp1,D-2-Nal4,Lys5(4-FB)]ipamorelin 1920 
Table 3. IC50 values of ipamorelin and a series of derivatives thereof. 
Surprisingly, the coupling of a 4-fluorobenzoyl group to the side-chain of lysine was 
found to slightly improve the IC50 value of ipamorelin (LCE00210) from 483 nM to 170 
nM (LCE00211). This could be due to the fact that the bulky fluorobenzoyl group may be 
decreasing ipamorelin binding to the polar sub-pocket of the GHS-R1a but increasing 
non-covalent interactions with aromatic residues (e.g. Phe220, Phe222 and Phe22684) in 
the non-polar sub-pocket. This would then promote stronger overall binding to the 
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receptor. An investigation into lengthening the lysine side-chain by way of introducing a 
short mini-PEG linker (aminoethanolethylamine, AEEA) between it and the 4-
fluorobenzoyl group (LCE00217) effectively “re-set” the IC50 value back to that of the 
parent compound ipamorelin (cf. 474 nM for LCE00217 to 483 nM for LCE00210). This 
is presumably the result of an increase in distance between the 4-fluorobenzoyl moiety 
and the aromatic residues in the non-polar sub-pocket mentioned previously. A 
compound with comparable affinity to the 4-FB-ipamorelin analogue was synthesized by 
replacement of the D-Phe residue with D-2-Thi, resulting in an IC50 = 161 nM ([D-2-Thi4, 
Lys5(4-FB)]ipamorelin, LCE00267). The rationale behind this modification was based on 
a paper by Hansen and co-workers which described the replacement of D-Phe with a D-2-
Thi amino acid for a series of tripeptide ipamorelin derivatives.69 This had the effect of 
reducing EC50 values by an order of magnitude.69 By assuming that a strong efficacy is 
indicative of a strong binding affinity, an improvement in the IC50 value was predicted. 
Instead, binding affinity was essentially retained (cf. 161 nM to 171 nM for LC00210). It 
may be hypothesized that because the aromatic character (resonance energy) of the 
thiophene functionality in D-2-Thi is similar to that of benzene in D-Phe (cf. 36 kcal/mol 
to 29 kcal/mol),107 π-stacking/hydrophobic interactions with the ghrelin receptor may be 
retained, leading to a very similar half-maximal inhibitory concentration. Next, the 
primary amine in the N-terminus of ipamorelin was replaced with the secondary amine 
isonipecotic acid (Inp) so as to make the resultant compound (LCE00268) similar to the 
Genetech peptidomimetic G-7039, known to have an EC50 = 0.18 nM.52 The increase in 
the IC50 value that resulted in moving from the primary amine (LCE00211, IC50 = 171 
nM) to the secondary amine (LCE00268, IC50 = 688 nM) could be explained by the fact 
that the salt bridge with the Glu124 residue in TM3 (polar binding pocket) would be 
more difficult to form due to an increase in steric hindrance.  
An order of magnitude reduction in binding affinity for the ghrelin receptor was found 
when the D-Phe residue and primary amine in LCE00211 were replaced with D-2-Nal 
and Inp respectively (LCE00269, IC50 = 1920 nM). This was carried out in order to probe 
the importance of the D-Phe residue in sub-pocket binding. The increase in the IC50 value 
may mean that the D-Phe residue is involved in similar π- π or hydrophobic interactions 
with Phe119 (TM3, polar sub-pocket) as the very same residue in the active tetrapeptide 
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core of ghrelin.84, 87A similar reduction in binding affinity is achieved by introducing a 
secondary amine into the N-terminus of the peptide (Inp) along with a D-2-Thi moiety 
([Inp1,D-2-Thi4,Lys5(4-FB)]ipamorelin, IC50 = 1170 nM). Both of these modifications 
may be making the resulting compound (LCE00246) unrecognizable to either binding 
domain of the GHS-R1a. In spite of the slight improvements made to the binding affinity 
of ipamorelin, it is clear that the 4-fluorobenzoyl modification does not yield the desired 
IC50 of < 100 nM. Attention was therefore turned to peptidomimetic agonists with much 
lower initial IC50 values.  
Previous work on the most well-known GHRPs (GHRP-1, GHRP-2 and GHRP-6) 
indicated that this series of peptides could be amenable to the same amino group 
fluorobenzoylation that ipamorelin was subjected to. This was shown by the low 
nanomolar Ki values that were acquired for GHRP-6 and GHRP-2 (3.3 nM and 1.4 nM 
respectively) in a recent study by Pinyot et al., using HEK293/GHS-R1a cells.106 All 
three of the compounds were assayed to determine their IC50 values as this is not directly 
comparable to the known literature binding affinity (Ki). Table 4 shows the results. 
LCE no. Compound Name IC50, nM 
00240 GHRP-1 181 
00282 GHRP-2 449 
00239 GHRP-6 73 
00272 [Lys6(4-FB)]GHRP-6 384 
00298 [Dpr6]GHRP-6 397 
00281 [Dpr6(4-FB)]GHRP-6 1060 
Table 4. IC50 values of GHRPs and their derivatives. 
It was discovered that out of the three peptides, Momany and Bowers’ first GHRP40 
(GHRP-6, H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) was found to have the strongest 
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binding affinity for the ghrelin receptor (IC50 = 73 nM, LCE00239) compared to GHRP-1 
(IC50 = 181 nM, LCE00240) and GHRP-2 (IC50 = 449 nM, LCE00282). This peptide was 
therefore transformed into the fluorobenzoylated congener [Lys6(4-FB)]GHRP-6 
(LCE00272). Conversely, this alteration was not accepted favourably by the GHS-R1a 
despite the previous success achieved with ipamorelin (IC50 = 384 nM compared to IC50 = 
171 nM for [Lys5(4-FB)]ipamorelin). One possible reason for this is that GHRP-6 only 
binds to the polar sub-pocket (or has a very strong selectivity for it)82 and thus an attempt 
to change its sub-pocket selectivity will simply prevent it from binding to the ghrelin 
receptor rather than making it preferentially bind to the non-polar sub-pocket. In an effort 
to increase affinity for the ghrelin receptor, the lysine side-chain of GHRP-6 was 
shortened by replacing it with Dpr. As a consequence of this, the IC50 value for both the 
non-fluorobenzoylated derivative ([Dpr6]GHRP-6, LCE00298) and the fluorobenzoylated 
congener ([Dpr6(4-FB)]GHRP-6, LCE00281) increased considerably (397 nM and 1060 
nM respectively). A larger increase was observed for [Dpr6(4-FB)]GHRP-6 compared to 
[Dpr6]GHRP-6 indicating that the combination of a Dpr residue and a 4-fluorobenzoyl 
group had a more negative impact on receptor binding compared to the Dpr residue in 
isolation. Not only does the lysine side-chain appear to be an important pharmacophoric 
site for receptor binding in GHRP-6 (an observation at odds with the results from Huang 
et al’s study83 and those obtained for ipamorelin), but the length of the alkyl chain also 
seems to play an important role. Given that the IC50 values for GHRP-1 (181 nM) and 
GHRP-2 (449 nM) were considerably higher that of GHPR-6 (73 nM) and the subsequent 
failure of GHRP-6 fluorobenzoylation, further derivatization of this class of 
peptidomimetics agonists was not pursued.   
The final peptidomimetics that were investigated in this study were two Genentech 
pentapeptides: G-7039 (H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2) and [1-Nal4]G-7039 (H-
Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2). These compounds were chosen as a consequence 
of the fact that they both showed low nanomolar efficacy in a series of rat pituitary cell 
assays looking at GH release (EC50 = 0.18 nM for G-703952 and 0.10 nM for [1-Nal4]G-
7039,108 respectively). The synthesized benzoyl congeners can be seen in Table 5. 
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LCE no. Compound Name IC50, nM 
00245 G-7039 5.2 
00243 [Lys5(4-FB)]G-7039 242 
00244 [1-Nal4]G-7039 28 
00270 [1-Nal4,Lys5(4-FB)]G-7039 69 
Table 5. IC50 values of Genentech peptidomimetics and their derivatives. 
A cursory glance at Table 5 shows that in both cases the coupling of 4-[19F]FBA to the 
lysine side-chain of the Genentech peptidomimetics results in a reduced binding affinity. 
What is interesting to note is that whilst blocking the lysine side-chain of G-7039 with 
para-fluorobenzoic acid has the effect of increasing the half-maximal inhibitory 
concentration by almost two orders of magnitude (5.2 nM for G-7039 to 242 nM for 
[Lys5(4-FB)]G-7039) only a minor increase in the IC50 value is seen for [1-Nal4]G-7039 
(28 nM to 69 nM for [1-Nal4,Lys5(4-FB)]G-7039). This is a significant finding, as both 
G-7039 and [1-Nal4]G-7039 differ only in a single residue; the former compound 
contains a Phe and the latter a 1-Nal. It is therefore clear that such a considerable change 
in binding affinity with fluorobenzoylation signifies that G-7039 may be selective for the 
GHS-R1a polar sub-pocket and [1-Nal4]G-7039 for the aromatic sub-pocket. 
Nevertheless, despite the decrease in the half-maximal inhibitory concentration of both 
compounds, [1-Nal4,Lys5(4-FB)]G-7039 represents the first lead compound to be 
synthesized in this study focusing on the insertion of the 4-fluorobenzoyl moiety into a 
number of specific peptidomimetics containing a free lysine side-chain. This is because it 
has a sufficiently low nanomolar IC50 value (69 nM < 100 nM) to be investigated further. 
In summary, the introduction of a 4-fluorobenzoyl moiety into the series of 
peptidomimetic GHS-R1a agonists examined here generally has the effect of weakening 
the binding affinity for the receptor (G-7039, [1-Nal4]G-7039 and GHRP-6) with the 
exception of ipamorelin. What is also apparent is that even minute changes to the 
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structure of the peptidomimetic agonists can have a significant impact on binding affinity 
(see previous discussion on G-7039 and [1-Nal4]G-7039). The 4-fluorobenzoylation 
approach described within this section enabled the identification of the peptidomimetic 
[1-Nal4,Lys5(4-FB)]G-7039 as a lead compound. This peptidomimetic will act as a “cold” 
standard that will be evaluated in a number of in vitro tests prior to 18F-radiolabelling of 
the parent peptidomimetic [1-Nal4]G-7039 with [18F]FBA or [18F]SFB. The in vitro 
assays that are to be performed include calculating partition coefficients and determining 
efficacy. These tests are important in anticipating the behaviour of the lead 
peptidomimetic [1-Nal4,Lys5(4-FB)]G-7039 in vivo before synthesizing the “hot” 
congener by 18F-radiolabelling. 
2.4.1.3 4-FB Agonist Partition Coefficients  
The requirement for a lead peptidomimetic GHS-R1a agonist to have a binding affinity of 
< 100 nM for the ghrelin receptor is not the only factor that is crucial in developing it into 
an imaging agent. One of these additional factors is the compound’s lipophilicity.  
Generally speaking, the lipophilicity (or hydrophobicity) of a compound is expressed as a 
ratio of the molecule’s distribution in a mixture of n-octanol and water. This distribution 
is known as the “partition coefficient,” P (Eqn 1).80 
P = [compound	in	݊ − octanol)[compound	in	water] 															(1) 
Hydrophilic molecules tend to have a higher concentration in water, thereby resulting in 
low P values. The opposite is true for hydrophobic compounds.80 The partition coefficient 
is usually expressed as the logarithm of P (logP), a dimensionless quantity where 
favourable values for drugs or imaging agents are in the range of 1-3,109 implying that 
hydrophobicity is preferred. This propensity for hydrophobicity can be explained based 
on the fact that as it increases, lead compounds are better able to cross biological barriers 
and interact with target receptors.80 In other words, an improvement in biological activity 
often results.80 On the one hand, this increase is especially important for imaging agents, 
as a rise in hydrophilicity is more likely to lead to non-specific binding.2 This would in 
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turn result in reduced target visualization, increased background image contrast as well as 
higher toxicity in vivo.80 On the other hand, if the logP value is too high, the imaging 
probe suffers from solubility issues and fast clearance from the body.80 Finding the 
correct range for logP is therefore critical in predicting the behaviour of lead compounds 
in the body. 
The lipophilicity of a specific compound can be determined in two ways: experimentally 
or computationally. The most accurate way of determining the logP value is through the 
“shake-flask” method.110 This technique essentially involves dissolution of the compound 
in a pre-equilibrated 1:1 mixture of n-octanol and water, taking aliquots after a specified 
period of time and finding the concentration of the compound in each phase using 
HPLC.110 Unfortunately this particular method suffers from a number of drawbacks. 
Firstly, it is labour intensive, expensive and frequently time-consuming as each sample 
has to be run in triplicate.111 Secondly, complete dissolution of the sample is required, 
which is often difficult to observe when only small quantities are available. In addition, 
many of the hydrophobic peptidomimetics synthesized in this chapter have solubility 
issues in water. For these reasons a computational approach for determining lipophilicity 
was taken. 
The logP values for the 4-FB peptidomimetic GHS-R1a agonists were thus determined 
using ACD/LogP112, 113 and XLOGP3114 computer software. These programs were chosen 
based on a study by Thompson and co-workers,111 where a comparison was made 
between seven fragment-based computational programs and their degree of accuracy in 
predicting logP within ± 0.5 to ± 1.0 log units of an experimentally determined value.111 
The experimental database was exclusively composed of peptides of varying length and 
type (blocked, unblocked and cyclic).111 Both programs scored highest with blocked 
peptides, which as a class of compounds most accurately represent the 4-fluorobenzoyl 
growth hormone secretagogues synthesized here.111  
In terms of calculating lipophilicity, ACD/LogP uses an experimental data set of over 
18,000 logP measurements and predicts lipophilicity using an additive-constitutive 
algorithm.112, 113 This algorithm takes into consideration contributions from individual 
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atoms as well as fragments.112, 113 XLOGP3 computes the logP value of the desired 
compound by using a knowledge-based atom-additive model and is calibrated using a 
training set of 8199 organic compounds.114 Table 6 lists the results of the computational 
calculations for the 4-FB peptidomimetic ghrelin receptor agonists. 
LCE number Peptidomimetic LogP (ACD/LogP) LogP (XLOGP3) 
00210 Ipamorelin 1.72 ± 0.85 1.76 
00211 [Lys5(4-FB)]ipamorelin 3.97 ± 0.89 3.78 
00217 [Lys5(AEEA-4-FB)]ipamorelin 2.80 ± 0.93 2.83 
00239 GHRP-6 1.51 ± 0.88 1.92 
00240 GHRP-1 2.60 ± 0.90 2.79 
00243 [Lys5(4-FB)]G-7039 7.53 ± 0.88 7.20 
00244 [1-Nal4]G-7039 6.51 ± 0.82 6.44 
00245 G-7039 5.28 ± 0.82 5.19 
00246 [Inp1,D-2-Thi4,Lys5(4-
FB)]ipamorelin 
3.60 ± 0.89 3.84 
00267 [D-2-Thi4,Lys5(4-
FB)]ipamorelin 
3.65 ± 0.90 3.50 
00268 [Inp1,Lys5(4-FB)]ipamorelin 3.92 ± 0.89 4.13 
00269 [Inp1,D-2-Nal4,Lys5(4-
FB)]ipamorelin 
5.15 ± 0.89 5.38 
00270 [1-Nal4,Lys5(4-FB)]G-7039 8.76 ± 0.88 8.45 
00272 [Lys6(4-FB)]GHRP-6 3.76 ± 0.92 3.93 
00281 [Dpr6(4-FB)]GHRP-6 3.86 ± 0.93 2.86 
00282 GHRP-2 3.41 ± 0.86 3.27 
00298 [Dpr6]GHRP-6 1.61 ± 0.89 0.84 
Table 6. Computationally calculated logP values for 4-FB peptidomimetic GHS-R1a 
agonists. ACD/logP states logP values as ± standard deviation. 
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A number of general trends can be seen from the table above. Firstly, the difference 
between the computed logP of both programs is small (≤ 1.0 log units), resulting from the 
fact that both use a fragment-based approach to calculate lipophilicity. Secondly, the 
introduction of a 4-fluorobenzoyl functionality into a “parent” peptidomimetic (e.g. [1-
Nal4]G-7039) leads to in an increase in hydrophobicity for all derivatives (+ 2.25 for  
ACD/LogP and +2.01/2.02 for XLOGP3). Thirdly, most of the parent peptidomimetics 
possess a favourable logP value in the 1-3 unit range mentioned previously. The only 
exception to this is G-7039 (5.28 ± 0.82, 5.19) and [1-Nal4]G-7039 (6.51 ± 0.82, 6.44), 
which can be attributed to the smaller size of the peptidomimetics and prevalence of 
strongly hydrophobic aromatic residues (D-2-Nal, 1-Nal, Phe). 
Unfortunately, the lead compound [1-Nal4,Lys5(4-FB)]G-7039 possesses a very high 
logP value (8.76 ± 0.88 for ACD/LogP and 8.45 for XLOGP3). This suggests that it is 
not suited for in vivo PET imaging because it may cause a high degree of non-specific 
binding as well as suffering from potential solubility issues. Nevertheless, the logP value 
is not an exact predictor of compound behaviour in vivo, owing to criticism for the use of 
n-octanol as an organic phase.111 N-octanol does not adequately isolate hydrophobic 
interactions from different non-covalent interactions as it still retains a high degree of 
water.111 In addition, [1-Nal4,Lys5(4-FB)]G-7039 possesses a considerably lower IC50 
value compared to the next best compound [D-2-Thi4,Lys5(4-FB)]ipamorelin (cf. 69 nM 
to 161 nM) and therefore, despite its unfavourable lipophilicity, it was still carried 
forward for further in vitro assays. 
2.4.1.4 Calcium Flux Assay 
The second in vitro assay performed on the 4-fluorobenzoyl lead agonist was a calcium 
flux dose-response assay. This experiment allows the determination of the half-maximal 
effective concentration (EC50) for [1-Nal4,Lys5(4-FB)]G-7039, a measure of the 
concentration of the agonist required to produce 50% of the maximum biological effect 
resulting from ghrelin receptor activation.80 In this particular case, the biological effect of 
the peptidomimetic [1-Nal4,Lys5(4-FB)]G-7039 is the release of intracellular calcium 
ions, a process which is detected by fluorescence using a FLIPRTETRA instrument (see 
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experimental section 4.3 for more details). Endogenous ghrelin was used as a control in 
this assay, which was performed by EMD Millipore’s GPCRProfiler® service. The data 
acquired is presented in Figure 14. 
 
Figure 14. Efficacy curves for lead agonist [1-Nal4,Lys5(4-FB)]G-7039 (circles) and the 
control ligand ghrelin (squares). 
The control ligand ghrelin was found to have a low in vitro potency (EC50 = 1.6 nM), 
which is expected for the endogenous ligand of the GHS-R1a. The EC50 value of [1-Nal4, 
Lys5(4-FB)]G-7039 was found to be 1.1 nM. This demonstrates that the presence of the 
4-fluorobenzoyl group still results in a low nanomolar efficacy. This is in spite of the 
slight increase in the IC50 value compared to the parent compound [1-Nal4]G-7039 (IC50 
= 69 nM vs 28 nM respectively). The low in vitro potency acquired for [1-Nal4,Lys5(4-
FB)]G-7039 indicates that it is a potent ghrelin receptor agonist. 
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2.4.1.5 18F-Radiochemistry 
The initial approach to radiolabelling the precursor compound [1-Nal4]G-7039 employed 
the radioactive compound [18F]FBA. This prosthetic group has been used to radiolabel 
resin-bound peptides in the solid-phase,97, 100 but literature evidence for radiolabelling in 
solution appears to be sparse. In order to couple [18F]FBA to a peptide, pre-activation 
using a coupling reagent such as 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate (HATU) or HCTU is required. This enables 
formation of the active ester of [18F]FBA (through the same mechanism as for an amino 
acid) that can then be nucleophilically attacked by the desired group on the peptide.  
Past attempts at solution-phase radiolabelling of GLP-1 analogues with [18F]FBA in our 
laboratory were met with limited success.115 Despite these drawbacks, solution-phase 
coupling of 4-[19F]FBA to the lysine side-chain of [1-Nal4]G-7039 using the coupling 
reagent HATU in DMF resulted in fluorobenzoylated product after 5 minutes. This can 
be seen in the crude HPLC UV trace (Figure 15).  
 
Figure 15. Crude HPLC UV trace of the reaction between [1-Nal4]G-7039 and 4-
[19F]FBA in DMF. 
 
DMF 
[1-Nal4]G-7039 Product 
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The retention time and mass of the product at 8.84 minutes corresponds to that of [1-Nal4, 
Lys5(4-FB)]G-7039 made by solid-phase peptide synthesis, thereby confirming that site-
selective fluorobenzoylation has occurred at the side-chain of lysine as opposed to the N-
terminus of the secondary amine. This is because the retention time of the N-terminally 
flurobenzoylated species would be different. As a consequence of the successful 
formation of the cold lead compound [1-Nal4,Lys5(4-FB)]G-7039, coupling of [18F]FBA 
to the lysine side-chain of the precursor [1-Nal4]G-7039 was pursued.  
In order to synthesize the [18F]FBA prosthetic group, the cold precursor triflate salt was 
first obtained by the synthetic pathway shown below (Scheme 4). Acid catalysed 
esterification of the 4-dimethylaminobenzoic acid starting material 26 afforded the 
intermediate t-butyl ester 27. The tertiary amine of this compound was then methylated 
with MeOTf (under a blanket of nitrogen) to give the final product triflate salt 28. This 
compound was acquired in a yield of 38% and > 95% purity by UHPLC. 
 
Scheme 4. Synthesis of the precursor 4-(tert-butoxycarbonyl)-N,N,N-
trimethylbenzenammonium triflate salt. Reagents and Conditions: a) i) trifluoroacetic 
anhydride, THF, 0°C ii) tBuOH, room temperature, 2 hrs b) MeOTf, N2, 0°C, 1 hour. 
Having synthesized the precursor salt 28, 18F-radiolabelling was initiated. The pathway to 
the [18F]FBA prosthetic group is outlined in Scheme 5. The first step in this procedure 
involved nucleophilic aromatic substitution of the triflate salt 28 with the [18F-] anion 
acquired from the PET cyclotron by irradiation of [18O]H2O (the so-called 18O(p,n)18F 
nuclear reaction). This led to the formation of radioactive compound 29. Acid-catalysed 
de-esterification furnished the prosthetic group [18F]FBA 30 after 5 minutes. This was 
then reacted with the peptidomimetic precursor agonist [1-Nal4]G-7039 for 20 minutes 
via the solution-phase coupling procedure previously used with 4-[19F]FBA. After 20 
minutes, an analytical HPLC was run in order to check the progress of the reaction. 
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Scheme 5. Synthesis of [18F]FBA and attempted coupling to precursor peptidomimetic 
[1-Nal4]G-7039. Reagents and Conditions: a) K 222, K2CO3, [18F]-, DMSO, 120°C, 10 
minutes; b) 5M HCl, 120°C, 5 minutes; c) [1-Nal4]G-7039, 0.023 M HATU/DMF, 4.8 % 
DIPEA/DMF, DMF, room temperature, 20 minutes. 
As no product was observed in the radio-chromatogram, an additional aliquot of 
DIPEA/DMF and HATU/DMF were added. This failed to yield a fluorobenzoylated 
product after a further 20 minutes. Co-injection of the cold standard 4-[19F]FBA and 
[18F]FBA showed that formation of the latter “hot” prosthetic group was successful 
(Figure 16, overleaf) in spite of the failure of the coupling reaction with [1-Nal4]G-7039. 
Seeing as the coupling strategy employing pre-activation of [18F]FBA with HATU did 
not succeed, no further attempts were made. 
Following the failure of the preceding 18F-radiolabelling strategy, an alternative method 
involving [18F]SFB was exploited. This molecule is by far the most commonly used 18F-
radiolabelled prosthetic group for functional group acylation in the literature. It is 
typically used to acylate N-terminal and side-chain amino groups of peptide residues as 
well as small molecules.116-118 One of the main advantages of [18F]SFB is that unlike 
[18F]FBA, it does not require pre-activation with HATU or HCTU as it is already present 
as an active N-hydroxysuccinimide (NHS) ester. In addition, [18F]SFB may be prepared 
in a short period of time (1 hour) and in a facile manner using only three synthetic steps.99 
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Figure 16. A series of chromatograms resulting from the co-injection of cold standard 4-
[19F]FBA (λ = 254 nm) and crude “hot” product [18F]FBA.  
Furthermore, the synthesis of [18F]SFB was recently optimised to a short reaction time 
(68 minutes) and reproducible radiochemical yields (34-38 %) thorough the use of a 
remotely controlled synthesis module.99 This enabled the production of large quantities of 
[18F]SFB which would otherwise be dangerous by manual radiosynthesis. The synthetic 
pathway herein was initiated by [18F]FBA synthesis utilizing the procedure outlined in 
Scheme 5 above. This was followed by coupling of the crude fluorobenzoyl group to 
NHS (step a, Scheme 6). 
The [18F]FBA (30) was coupled to NHS using the coupling reagent N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) which led to the formation of the 
[18F]SFB prosthetic group 32. The NHS leaving group pre-activates the radiolabelled 
product towards nucleophilic attack when coupling with [1-Nal4]G-7039. 
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Scheme 6. Synthesis of the [18F]SFB prosthetic group and subsequent 18F-radiolabelling 
of [1-Nal4]G-7039. Reagents and Conditions: a) EDC, NHS, MeCN, room temperature, 
10 minutes; b) [1-Nal4]G-7039, DIPEA, MeCN/H2O 1:1, 50-70°C, 15 minutes. 
The crude 18F-radiolabelled prosthetic group 32 was purified by reverse-phase HPLC 
(35-60 % MeCN + 0.1% TFA gradient system, with retention time Rt = 9.3 mins) to give 
a decay-corrected radiochemical yield of 59%. An analytical HPLC (25-90% MeCN + 
0.1% TFA) was performed to check the radio-purity of the final compound, which was 
found to be > 99%. The radio-chromatogram for pure [18F]SFB can be seen in Figure 17.  
The pure [18F]SFB was finally added to the peptide precursor [1-Nal4]G-7039 in a 1:1 
mixture of MeCN/H2O using a small quantity of the hindered base DIPEA. After 15 
minutes, the crude [1-Nal4,Lys5(4-[18F]-FB)]G-7039 lead compound was obtained. This 
was then purified using the same gradient system as for [18F]SFB (35-60 % MeCN + 
0.1% TFA, Rt = 12.3 mins). The final radiolabelled peptide [1-Nal4,Lys5(4-[18F]-FB)]G-
7039 (33) was obtained in a decay-corrected radiochemical yield of 52% with a 
radiochemical purity of > 98% and reaction time of 127 minutes after the end-of-
synthesis (EOS). Figure 18 displays a series of stacked chromatograms including the cold 
standard [1-Nal4,Lys5(4-FB)]G-7039, the peptidomimetic precursor [1-Nal4]G-7039 as 
well as the radiolabelled [1-Nal4,Lys5(4-[18F]-FB)]G-7039 lead peptidomimetic. The 
retention times of the cold standard and hot peptide are almost identical ([1-Nal4,Lys5(4-
FB)]G-7039, Rt = 6.70 mins compared to Rt = 6.65 mins for the hot peptide), indicating 
that the precursor [1-Nal4]G-7039 has been selectively radiolabelled at the amino group 
of the lysine side-chain. 
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Figure 17. HPLC radio-chromatogram of pure [18F]SFB. 
 
Figure 18. Stacked HPLC Chromatograms for [1-Nal4]G-7039, [1-Nal4,Lys5(4-FB)]G-
7039 (both λ = 254 nm) and [1-Nal4,Lys5(4-[18F]-FB)]G-7039. 
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Further evidence for successful coupling of [18F]SFB to [1-Nal4]G-7039 via the lysine 
side-chain was provided by a co-injection of a pre-mixed solution with a 1:1 ratio of the 
cold standard and “hot” peptidomimetic. This was carried out in order to make sure that 
minor changes in HPLC pressure between analytical runs were not causing accidental 
alignment of [1-Nal4,Lys5(4-[18F]-FB)]G-7039 with any by-products present in [1-Nal4, 
Lys5(4-FB)]G-7039 (Figure 19 overleaf). The co-injection again showed very similar 
retention times between the two peptidomimetic species ([1-Nal4,Lys5(4-FB)]G-7039 Rt 
= 6.26 mins and [1-Nal4,Lys5(4-[18F]-FB)]G-7039 Rt = 6.17 mins) lending further 
credence to regioselective 18F-fluorobenzoylation at the lysine side-chain. One possible 
reason for this selectivity may be the increase in steric crowding afforded by the 
secondary amine of isonipecotic acid in the N-terminus of [1-Nal4]G-7039. This factor, 
coupled with the steric bulk of [18F]SFB (as well as the fact that the lysine side-chain is 
quite far removed from the core of the peptidomimetic) could explain why regioselective 
coupling of [18F]SFB appears to be selective for the lysine side-chain of [1-Nal4]G-7039.  
 
Figure 19. Stacked HPLC chromatograms resulting from the co-injection of cold 
standard [1-Nal4,Lys5(4-FB)]G-7039 (λ = 254 nm) and [1-Nal4,Lys5(4-[18F]-FB)]G-7039. 
45 
 
Finally, a calibration curve was set-up at four different concentrations (0.46 μM, 0.92 
μM, 4.6 μM and 9.2 μM) for the cold standard [1-Nal4,Lys5(4-FB)]G-7039. For each 
concentration, an analytical HPLC was run a minimum of two times in order to achieve 
area under the curve (AUC) values within 5% of each other. This curve is shown in 
Figure 20 and enables determination of the specific activity of the radioactive lead 
compound [1-Nal4,Lys5(4-[18F]-FB)]G-7039. By solving the equation for a straight line 
for х (the concentration of the cold lead compound [1-Nal4,Lys5(4-FB)]G-7039), and 
knowing the final volume of the hot peptide acquired (3 ml) the specific activity was 
found to be equal to 116 MBq/μmol. 
 
Figure 20. Calibration curve for cold standard [1-Nal4,Lys5(4-[18F]-FB)]G-7039. 
2.4.1.6 Conclusions 
In summary, the 4-[19F]-FBA prosthetic group was inserted into the lysine side chain of a 
number of peptidomimetic GHSs (ipamorelin, GHRP-6, G-7039 and [1-Nal4]G-7039) in 
order to investigate possible sites for 18F-radiolabelling of these compounds. The primary 
aim of this strategy was to identify a GHS with an IC50 < 100 nM and secondly, to 
radiolabel the subsequent compound with fluorine-18. A series of receptor binding assays 
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utilizing HEK293/GHS-R1a cells with [125I]ghrelin as a competitive radioligand were 
performed in order to fulfil the primary aim. This resulted in the identification of the lead 
compound [1-Nal4,Lys5(4-FB)]G-7039 with an IC50 = 69 nM and a partition coefficient 
of 8.76 ± 0.88 (ACD/logP) and 8.45 (XLOGP3). A calcium flux assay established that 
agonist activity had been retained after blocking of the lysine side-chain with 4-[19F]-
FBA (EC50 = 1.1 nM). 18F-radiolabelling of the precursor parent compound [1-Nal4]G-
7039 with [18F]SFB led to the synthesis of [1-Nal4,Lys5(4-[18F]-FB)]G-7039 in a 
radiochemical yield of 52% and radiochemical purity of > 98% in a reaction time of 127 
minutes after EOS. The specific activity of the final radiotracer was 116 MBq/μmol. Both 
Figures 18 and 19 strongly imply successful regioselective coupling of the [18F]SFB to 
the lysine side-chain of the peptidomimetic GHS-R1a agonist [1-Nal4]G-7039. The lead 
compound [1-Nal4,Lys5(4-[18F]-FB)]G-7039 represents (to the best of our knowledge) the 
first 18F-radiolabelled ghrelin receptor agonist to be synthesized. With this radioactive 
compound, a significant step has been made towards PET imaging of the ghrelin receptor 
in prostate carcinoma, an achievement that should eventually lead to a clinically useable 
radiotracer that would also enable differentiation between BPH and PCa and play a vital 
role in early-stage PCa diagnosis 
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2.5 Alternative 18F-Radiolabelling Strategy 
A second approach for adding a 18F radioisotope into the lysine side-chain of the 
peptidomimetic GHS-R1a agonists was also explored. This involved the racemic 2-
fluoropropionyl moiety. This particular strategy was devised on the basis of a recent 
paper by Haskali and co-workers.119 They prepared the [18F]galacto-Arg-Gly-Asp 
radiotracer 34 (Figure 21) by prosthetic group radiolabelling of galacto-Arg-Gly-Asp 
with 4-nitrophenyl 2-[18F]fluoropropionate ([18F]NFP, 35) in a decay corrected 
radiochemical yield of 20%.119 This compound is currently the gold standard for PET 
imaging of the alpha-v beta-3 (αvβ3) integrin receptor.119  
 
Figure 21. [18F]GalactoRGD and [18F]NFP. 
When a comparison is made between the 4-fluorobenzoyl and 2-fluoropropionyl 
functionalities, the latter group is much more in line with the concept of the small 
innocuous 18F subunit that was discussed in section 2.4. As a consequence of this, it was 
hypothesized that the acetylation of the lysine side-chain of the peptidomimetic agonists 
with the 18F prosthetic group mimic  2-[19F]fluoropropionic acid (2-[19F]FPA)  should not 
affect GHS-R1a binding in the same manner as the 4-[19F]FBA prosthetic group. In other 
words, a smaller increase in the IC50 value would occur as the 2-fluoropropionyl group is 
smaller in size, less sterically hindered and therefore more likely to fit into one of sub-
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pockets of the ghrelin receptor that these peptidomimetics are selective for. The primary 
goal of this alternate lead compound identification strategy was to obtain a 
peptidomimetic GHS-R1a agonist with an IC50 value < 20 nM. 
2.5.1 Results and Discussion 
2.5.1.1 Synthesis of 2-FP Peptidomimetic GHS-R1a Agonists 
The Genetech peptidomimetics G-7039 and [1-Nal4]G-7039 were chosen to be modified 
with 2-[19F]FPA as they both have low nanomolar IC50 values (5.2 and 28 nM 
respectively) and should therefore be less prone to losing binding affinity for the ghrelin 
receptor by introducing a sterically less-crowded functionality.  These compounds were 
synthesized by Fmoc-SPPS using the same protocol outlined previously. The strategy for 
insertion of the 2-fluoropropionyl group was identical to that of the 4-fluorobenzoyl 
group, with the Alloc group being deprotected by palladium (see compound 36, Scheme 
7). Coupling of racemic 2-[19F]FPA was conducted for 1.5 hours and furnished a racemic 
mixture of the final peptidomimetic 38. 
 
Scheme 7. Orthogonal protecting group strategy and coupling of 2-[19F]FPA illustrated 
for the peptidomimetic G-7039 (36). 
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The 2-FP peptidomimetic GHS-R1a agonists were characterized by 1H-NMR, HRMS 
(ESI-TOF) and HPLC. Detailed characterization data is presented in Tables 7 and 8. 
Peptidomimetic LCE number Amino Acid Sequence 
G-7039 00245 H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2 
[Lys5(2-FP)]G-7039 00295 H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(2-FP)-NH2 
[1-Nal4]G-7039 00244 H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2 
[1-Nal4,Lys5(2-
FP)]G-7039  
00297 H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(2-FP)-
NH2 
Table 7. Amino acid sequences of the 2-fluoropropionyl agonists and their parent 
compounds. 
LCE 
number 
HRMS (calculated) 
[M + H]+ 
HRMS (found) 
[M + H]+ 
% 
Purity 
% 
Yield 
00245 798.4343 798.4339 > 99 7 
00295 872.4511 872.4516 > 99 13 
00244 848.4499 848.4501 > 99 23 
00297 922.4667 922.4651 > 99 7 
Table 8. Yields, purities and HRMS data for the 2-fluoropropionyl agonists and their 
parent compounds. 
The 2-fluoropropionyl peptidomimetic GHS-R1a agonists were obtained with purities > 
99 % by HPLC and yields of > 5%. Unlike the 4-fluorobenzoyl modification, 
fluoropropionylation of the lysine side-chain has a unique 1H-NMR signature. This 
consists of a doublet of quartets (dq) between 4.76-4.96 ppm resulting from the coupling 
of the methine proton to 19F and the methyl group on the α-carbon atom respectively 
(Figure 22). This particular downfield signal further confirms the successful coupling of 
the 2-fluoropropionyl group to the lysine side-chain and hence the synthesis of the 
peptidomimetic agonists [1-Nal4,Lys5(2-FP)]G-7039 and [Lys5(2-FP)]G-7039. 
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Figure 22. 1H-NMR signature of methine proton in [Lys5(2-FP)]G-7039 (LCE00295). 
2.5.1.2 2-FP Agonist Receptor-Ligand Binding Assays 
The binding assays were performed using the same procedure as was presented in section 
2.4.1.2. The results are tabulated below. 
 LCE no. Compound Name IC50, nM 
00245 G-7039 5.2 
00295 [Lys5(2-FP)]G-7039 19 
00243 [Lys5(4-FB)]G-7039 242 
00244 [1-Nal4]G-7039 28 
00297 [1-Nal4,Lys5(2-FP)]G-7039  105 
00270 [1-Nal4,Lys5(4-FB)]G-7039  69 
Table 9. 2-Fluoropropionyl Genentech peptidomimetic derivatives and their IC50 values. 
Methanol-d4 
Doublet of quartets 
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As can be seen from the table above, the introduction of the 2-fluoropropionyl group into 
lysine side-chain of G-7039 increased the IC50 value only by ~14 nM compared to ~200 
nM for the 4-fluorobenzoyl group (cf. 19 nM for LCE00295 to 242 nM for LCE00243). 
This indicates that fluoropropionylation of the lysine side-chain enables G-7039 to retain 
binding affinity for the polar sub-pocket of the ghrelin receptor, possibly because of the 
lower steric hindrance afforded by this moiety. Conversely, the opposite applies to [1-
Nal4]G-7039. Whilst the 4-fluorobenzoyl congener ([1-Nal4,Lys5(4-FB)]G-7039) has an 
IC50 = 69 nM, the 2-fluoropropionyl derivative possesses a higher IC50 value (105 nM, 
LCE00297) suggesting that the parent compound [1-Nal4]G-7039 has a strong selectivity 
for the non-polar sub-pocket of the ghrelin receptor. 
To conclude, the 2-fluoroproprionyl functionalization strategy has provided a second lead 
compound warranting further investigation ([Lys5(2-FP)]G-7039). This peptidomimetic 
possesses an IC50 = 19 nM. In addition, it was shown that this moiety (whilst being less 
sterically encumbered than the 4-fluorobenzoyl group) did not necessarily improve 
interactions between the parent compound and the GHS-R1a receptor binding pocket. An 
excellent example of this is functionalization of [1-Nal4]G-7039 to [1-Nal4,Lys5(2-FP)]G-
7039, where the IC50 value increased from 28 nM to 105 nM respectively. Finally, the 
fact that the 2-fluoropropionyl analogue of [1-Nal4]G-7039 ([1-Nal4,Lys5(2-FP)]G-7039) 
had reduced binding to the ghrelin receptor, but the fluorobenzoyl analogue of the same 
parent compound ([1-Nal4,Lys5(4-FB)]-G-7039) had a higher receptor binding affinity 
(with the opposite argument applying to G-7039) suggests that G-7039 and [1-Nal4]G-
7039 have a preference for the polar and non-polar GHS-R1a sub-pockets respectively. 
2.5.1.3 2-FP Agonist Partition Coefficients 
The hydrophobicity of the 2-fluoropropionyl analogues was evaluated using ACD/LogP 
and XLOGP3 computer software. The results are displayed in Table 10. In stark contrast 
to the 4-fluorobenzoyl agonist congeners ([Lys5(4-FB)]G-7039 and [1-Nal4,Lys5(4-
FB)]G-7039), the ACD/logP values of the 2-fluoropropionyl Genentech derivatives 
decrease from 5.28 ± 0.82 to 5.19 ± 0.88 for G-7039 and 6.51 ± 0.82 to 6.42 ± 0.88 for 
[1-Nal4]G-7039. 
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LCE number Peptidomimetic LogP (ACD/LogP) LogP (XLOGP3) 
00245 G-7039 5.28 ± 0.82 5.19 
00295 [Lys5(2-FP)]G-7039 5.19 ± 0.88 6.22 
00243 [Lys5(4-FB)]G-7039 7.53 ± 0.88 7.20 
00244 [1-Nal4]G-7039 6.51 ± 0.82 6.44 
00297 [1-Nal4,Lys5(2-FP)]G-
7039 
6.42 ± 0.88 7.47 
00270 [1-Nal4,Lys5(4-FB)]G-
7039 
8.76 ± 0.88 8.45 
Table 10. Lipophilicities of Genentech peptidomimetic agonists and their 2-
fluoropropionyl derivatives.  
The reverse appears to be true for logP values computed by XLOGP3, where an increase 
in lipophilicity is observed for G-7039 and [1-Nal4]G-7039 (in both cases an increase of 
+ 1.03). This could be a consequence of the different computational approaches taken to 
calculating logP, where XLOGP3 uses a more knowledge-based pathway requiring the 
input of compounds of similar structure to those being analysed.114 Regardless, the 
computed logP values are both still higher than the accepted range of 1-3.109 However, 
the logP value of the 2-fluoropropionyl lead compound [Lys5(2-FP)]G-7039 (5.19 ± 0.88, 
6.22) represents a small improvement compared to the 4-fluorobenzoyl lead compound 
[1-Nal4,Lys5(4-FB)]G-7039 (8.76 ± 0.88, 8.45), suggesting that the former agonist could 
be better suited to in vivo PET imaging as it would benefit from enhanced solubility and 
reduced non-specific binding.  
2.5.1.4 Calcium Flux Assay 
Analogously to the 4-fluorobenzoyl lead compound [1-Nal4,Lys5(4-FB)]G-7039, the 
[Lys5(2-FP)]G-7039 lead was evaluated in a calcium flux assay for its in vitro potency 
(Figure 23). 
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Figure 23. Efficacy curves for the peptidomimetic GHS-R1a agonist [Lys5(2-FP)]G-7039 
(circles) and the control ligand ghrelin (squares). 
The EC50 value was found to be 20 pM, which is an exceptionally low efficacy for this 
peptidomimetic agonist. This correlates well with the reported half-maximal efficacy of 
the parent compound G-7039 (EC50 = 0.18 nM52) despite the different mode of potency 
determination (Ca2+ release for [Lys5(2-FP)]G-7039 but GH release for G-7039).  
2.5.1.5 Conclusions 
In this alternative 18F radiolabelling strategy, an aliphatic 2-fluoropropionyl prosthetic 
group was incorporated into the lysine side-chain of the peptidomimetic GHS-R1a 
agonists. This process resulted in the identification of a second lead peptidomimetic with 
a low nanomolar binding affinity (LCE00295, [Lys5(2-FP)]G-7039, IC50 = 19 nM). The 
computation of the logP value of this agonist using ACD/logP and XLOGP3 furnished 
partition coefficients of 5.19 ± 0.88 and 6.22 respectively. The differences in the logP 
values could be a consequence of the contrasting computational approaches taken by each 
piece of software in computing hydrophobicity. Further evaluation of [Lys5(2-FP)]G-
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7039 by an in vitro calcium flux assay indicated that blocking of the amino group of the 
lysine side-chain with the 2-fluoropropionyl group gave a peptidomimetic with picomolar 
efficacy (EC50 = 20 pM). This value was found to be lower than the endogenous control 
ligand ghrelin (EC50 = 9.92 nM) and confirmed that [Lys5(2-FP)]G-7039 still behaves as 
an agonist. Research into an 18F-radiolabelling strategy via direct nucleophilic 
displacement of a bromine or tosylate leaving group in place of the 19F atom is currently 
underway.  
H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2
NHO
Br (OTs)
H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2
NHO
18F
a
39 40  
Figure 24. 18F-radiolabelling strategies being explored for the 2-fluoropropionyl lead 
compound [Lys5(2-FP)]G-7039. Reagents and Conditions: a) K 222, K2CO3, [18F]-, 
DMSO, 120°C. 
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Chapter 3  
The Future of Prostate Cancer Imaging 
3.1 Final Remarks 
Prostate cancer is the second most prevalent cancer in men, with an estimated 1.1 million 
new cases diagnosed worldwide in 2012.120 Excluding non-melanoma skin cancer, this 
represents a staggering 15% of all male cancer cases.120 Despite recent improvements in 
the diagnosis and staging of this carcinoma, the World Health Organization predicted 
about 7% of all deaths from cancer to be due to PCa in the year 2012.120 The introduction 
of the mpMRI exam utilizing functional magnetic resonance imaging, PET/MRI 
multimodality imaging and the development of novel PET/CT probes for imaging 
prostate cancer (e.g. 64Cu-CB-TE2A-AR06) have all aided in the identification and 
localization of cancerous tumours.15 In addition, these advancements have enabled 
clinicians to find treatment programs best suited to patients’ diagnoses. However, in spite 
of these successes and achievements, several problems still remain: the ability to detect 
recurrent prostate cancer after radical prostatectomy, limited tumour detection in the c-
zone of the prostate gland (which is not accessible by conventional diagnostic techniques 
such as the DRE exam) and most importantly of all, efficiently distinguishing between 
BPH and PCa. 
The area of molecular imaging possesses the potential to continually improve and 
develop imaging probes that would aid in the early-stage imaging of prostate cancer at a 
time when it is critical to decide between an aggressive treatment plan or to monitor 
prostate health through active surveillance and prostatic biopsies. One of the ways in 
which molecular imaging does this is in the synthesis of molecular probes (peptides, 
peptidomimetics and small molecules for example) that specifically target peptide 
receptors up-regulated in prostate cancer. There are a considerable number of these 
GPCRs overexpressed in PCa, but some of the main ones are the luteinizing hormone-
releasing hormone receptor (LHRH-R), the GRPr and the GHS-R1a.4 Recent papers by 
Wieser et al29 and Kroll and co-workers28 look at more advanced means of targeting these 
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receptors rather than using a traditional agonist approach. One of the ways in which these 
GPCRs are now being targeted is through the use of antagonist imaging probes that in 
some cases are known to give better imaging results in vivo when compared to agonists. 
For example, the PET/CT imaging probe 64Cu-CB-TE2A-AR06 developed by Wieser et 
al. that targets the GRPr had a higher prostate tumour uptake when compared to agonists 
of the same receptor in initial clinical studies.29 This probe also gave a more favourable 
image contrast.29 A hybrid ligand approach has also been developed by Kroll and co-
workers which combines the best aspects of an antagonist (strong receptor binding) and 
agonist (internalisation) into a single imaging entity.28 The subsequent 68Ga radiolabelled 
ligand benefits from an optimised distance between both targeting elements which led to 
excellent prostate tumour uptake and tumour retention in pre-clinical murine PET/CT 
studies.28  
In this thesis, an 18F-radiolabelled peptidomimetic GHS-R1a agonist imaging agent 
targeting the GHS-R1a expressed in prostate cancer was developed. This process began 
with the modification of a number of literature GHSs with the 4-[19F]FBA prosthetic 
group which eventually led to the synthesis and identification of a cold lead compound 
with a strong affinity for the ghrelin receptor ([1-Nal4,Lys5(4-FB)]G-7039, IC50 = 69 
nM). This peptidomimetic was evaluated for lipophilicity as well as retention of agonist 
activity. In the former case, a high logP value was found (8.76 ± 0.88 for ACD/logP and 
8.45 for XLOGP3) and in the latter an EC50 = 1.1 nM. This initial strategy culminated 
with the successful synthesis of the 18F-radiolabelled congener [1-Nal4,Lys5(4-[18F]-
FB)]G-7039 in radiochemical yields of 51-52%, a radiochemical purity > 98% and 
specific activity of 116 MBq/μmol in 127 mins at EOS.  
The second pathway to a PET imaging agent targeting the GHS-R1a involved 
modification of two Genentech peptidomimetics with the 2-[19F]FPA moiety. This 
resulted in the formation of the second lead [Lys5(2-FP)]G-7039 with an IC50 = 19 nM. 
Investigation into the logP value of this peptidomimetic showed that it has a lower value 
than [1-Nal4,Lys5(4-FB)]G-7039 (cf. 5.19 ± 0.88 and 6.22 for [Lys5(2-FP)]G-7039 to 
8.76 ± 0.88 and 8.45 for ACD/logP and XLOGP3 respectively). The calcium flux assay 
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also showed that the final peptidomimetic GHS-R1a agonist still maintained its agonist 
behaviour. 
Further evaluation of the peptidomimetic GHS-R1a agonist [1-Nal4,Lys5(4-[18F]-FB)]G-
7039 in pre-clinical PET mouse imaging will move this probe closer to clinical 
evaluation. The most important factors that will allow the development of a clinically 
useable probe for PET imaging of prostate cancer is absence of toxicity, lack of non-
specific binding, low background contrast ratio, fast-clearance and stability in vivo. 
Although these steps are yet to be carried out, the [1-Nal4,Lys5(4-[18F]-FB)]G-7039 probe 
described in this thesis was developed through a rigorous series of evaluations which 
began with the identification of the ghrelin receptor as a meaningful target for PCa 
imaging, careful design of the probe by consideration of structure activity relationships, 
biological evaluation through receptor-ligand binding assays and final radiolabelling with 
18F.  
The lead peptidomimetic GHS-R1a agonist [1-Nal4,Lys5(4-[18F]-FB)]G-7039 is the first 
18F PET imaging agent designed to target the ghrelin receptor overexpressed in prostate 
cancer. The synthesis of this compound represents a significant step towards solving the 
clinical dilemma of over-diagnosis and overtreatment of PCa, as well as distinguishing 
between malignant and benign disease.  
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4 Experimental 
4.1 General Information 
All reagents were obtained from commercial suppliers and used without further 
purification. Peptides were either synthesized manually or through the use of a 
Biotage® Syro Wave™ automated peptide synthesizer. Peptide vessels were shaken using 
an IKA® Vibrax VXR basic shaker with centrifugation performed on a Beckman 
Coulter™ Allegra X-30R or Fisher GS-6R centrifuge. In order to aid peptide dissolution, 
sonication of solutions was accomplished via a Bransonic® 2510R-MTH or Fisher F5-14 
ultrasonic cleaner. A Fisher 2052 Isotemp® machine was used to heat test tubes in the 
Kaiser Test. Peptides were cryodessicated using a Labconco® FreeZone Freeze Dry 
System. Accurate weighing was carried out on a Mettler-Toledo® XP6 microbalance. UV 
traces were obtained with a Waters 2487 UV/Vis Dual λ Absorbance Detector (170-900 
nm) and low-resolution mass spectra with a Micromass® Quattro micro™ API mass 
spectrometer (ESI-LC-MS). Peptide purification was achieved through HPLC (MeCN + 
0.1% TFA, H2O + 0.1% TFA solvent system). All peptides and small molecules obtained 
had a purity ≥ 95% as determined by HPLC or UHPLC analysis. A reverse-phase (RP) 
preparative C-18 column (SunFire™ OBD™, 19 x 150 mm or Agilent™ Zorbax® 21.2 x 
150 mm) was used for preparative HPLC, whilst a C-18 RP column (SunFire™, 4.6 x 
150 mm or Agilent™ Zorbax®, 4.6 x 150 mm) was used for analytical HPLC. Accurate 
mass spectrometry (HRMS) was carried out on a Finnigan™ MAT 8400 mass 
spectrometer (EI) for small molecules and on a Micromass LCT mass spectrometer (ESI-
TOF) for peptides. 1H NMR and 13C NMR spectroscopy were performed on a Mercury 
VX 400 machine at 400 and 100 MHz respectively. Chemical shifts are referenced to 
residual solvent, reported in ppm on a δ scale and all coupling constants quoted in hertz 
(Hz). 
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4.2 Experimental Procedures 
4.2.1 Manual Fmoc Solid-Phase Peptide Synthesis (Fmoc-SPPS) 
Rink amide MBHA resin (192 mg, 0.1 mmol, 1.0 eq., 0.52 mmol g-1 loading) was 
vortexed in DCM (2.0 ml, 1 min.), allowed to swell (15 mins) and solvent removed. This 
was followed by addition of DMF (2.0 ml), vortexing (1 min.) and removal of solvent. 
Deprotection of the Fmoc group was then performed. A solution of 20% piperidine/DMF 
(1.5 ml, v/v) was added to the resin and the subsequent mixture vortexed (2 mins) and 
solvent removed. This was then repeated a second time with vortexing for 15 minutes. 
After solvent had been removed, the resin was washed of any unreacted by-products with 
DMF six times (2.0 ml, vortex 30 s). The desired amino acid or small molecule (0.3 
mmol, 3.0 eq.) and coupling reagent (HCTU, 0.12 g, 0.3 mmol, 3.0 eq.) were then 
dissolved in DMF (1.5 ml) and added to the deprotected resin. After vortexing (30 s), 
DIPEA (111 μl, 0.6 mmol, 6.0 eq.) was added and the final mixture vortexed (1-2 hrs). 
The resin was then washed with DMF (2.0 ml, 30 s vortex) a final four times. The 
deprotection/coupling cycle was then repeated unless the final amino acid in the sequence 
had been added, in which case the peptide was washed with DCM five times (2.0 ml, 30 s 
vortex) after washing with DMF and stored in a refrigerator. Removal of the N-terminal 
Fmoc-group was carried out in the same fashion as the deprotection cycle described 
previously, with resin washing occurring six times with DMF (2.0 ml, 30 s vortex) and 
four times with DCM (2.0 ml, 30 s vortex). Successful synthesis of the desired peptide 
was then ascertained via a microcleave prior to full cleavage of the peptide from the 
solid-support. This was carried out as follows: a solution of 95% TFA: 2.5% (iPr)3SiH: 
2.5% H2O (300 μl) was added to a small number of resin beads (< 5 mg) and the 
subsequent mixture vortexed (3 hrs). The clear liquid was then evaporated under a stream 
of N2. Analytical HPLC was then performed to determine whether the correct peptide had 
been synthesized. If the correct peptide had been obtained, a full cleavage was performed 
using a mixture of 95% TFA: 2.5% (iPr)3SiH: 2.5% H2O (2.0 ml) for 5-7 hrs. The 
subsequent solution was cooled in an ice-bath alongside tert-butyl methyl ether (TBMe, 
40 ml). After 10 minutes, TBMe (20 ml) was added to the peptide solution, leading to the 
formation of a white precipitate. The precipitate was cooled further (10 mins) and then 
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centrifuged (7 mins). Decanting of the supernatant was followed by addition of a second 
aliquot of TBMe (20 ml), vortexing (30 s) and final centrifugation (7 mins). After 
decanting, a white solid was obtained. This was then freeze-dried (20 mins) to furnish 
crude peptide. Preparative HPLC was then used to purify the product peptide. 
4.2.2 Deprotection of the Alloc Protecting Group 
The resin-bound peptide was vortexed in DCM (4.5 ml, 30 s) and allowed to swell (10 
mins). Deprotection was carried out under a blanket of N2. The swollen resin-bound 
peptide was stirred (5 mins) before addition of PhSiH3 (296 μl, 2.4 mmol, 24.0 eq.). 
Further stirring (5 mins) ensued prior to treating with Pd(PPh3)4 (120 mg, 0.01 mmol, 0.1 
eq.). The reaction mixture changed colour from yellow to orange to brown to dark brown. 
After 5 minutes, the solution was vortexed (5 mins), solvent removed and the brown-
coloured resin washed four times with DCM (2.0 ml, 30 s vortex). The procedure was 
then repeated ab initio, with final resin washing occurring in the following order: DCM, 
DMF, MeOH, DMF and DCM (all 2.0 ml, 30 s vortex). 
4.2.3 Kaiser Test 
The Kaiser test101 was used as a qualitative test to determine the success of amino acid 
coupling. A small number of resin beads (< 5 mg) were taken and treated with phenol: 
EtOH (200 μl, 8:2 v/v), 0.001 M KCN(aq.): pyridine (200 μl, 2:98 v/v, 0.001 M aqueous 
KCN) and ninhydrin in EtOH (200 μl, 5% w/v) respectively. Tentagel resin (< 5 mg) was 
used as a control in this test. Both test tubes were heated to 70 °C. The presence of free 
amine was indicated by blue resin beads whilst yellow or clear resin beads showed 
protected amine groups to be present. 
4.2.4 Receptor-Ligand Binding Assay 
Competitive binding assays were run at the Lawson Health Research Institute at St. 
Joseph’s Health Care in London Ontario, Canada. These were carried out in triplicate 
using HEK293/GHS-R1a cells (prepared by our collaborator Becky McGirr) with 
[125I]ghrelin as a competitive radioligand. To begin with, a fresh solution of binding 
61 
 
buffer (50 ml) was made up by adding 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic 
acid, N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid (HEPES, 0.3 g, 25 mM), 
MgCl2 (0.051 g, 5 mM), CaCl2 (7.4 x 10-3 g, 1 mM), ethylenediaminetetraacetic acid 
(EDTA, 0.015 g, 2.5 mM) and bovine serum albumin (BSA, 0.2 g, 0.4%) to distilled 
water. The resultant solution was mixed over gentle heat (< 100 °C). The pH was then 
adjusted to 7.4 and the solution filtered through a 0.22 μm syringe filter. Two miniature 
complete protease inhibitor tablets were then added and the final buffer solution kept on 
ice.   
After the buffer had been made, plastic assay test tubes were labelled and kept on ice 
during the setup. To assay tubes 1-21, 25-27 and 28-30 was added binding buffer (200 µl, 
230 µl and 300 µl respectively). No buffer was added to tubes 22-24. An aliquot of 
frozen cells was thawed to room temperature, centrifuged (3000 xg, 10 mins, room 
temperature) and the subsequent cell pellet re-suspended in binding buffer (2 ml) and 
placed on ice. Cells (50 µl) were then added to test tubes 1-21 and 25-27. Cold peptide 
was then prepared. This was carried out by adding pre-prepared stock peptide in water 
(20 µl, 10-3 M) to binding buffer (180 µl) to make a peptide solution of 10-4 M 
concentration. Binding buffer (180 µl) was then added to assay tubes labelled 10-5 to 10-
11. A series of dilutions were then performed in order to acquire 10-5 to 10-11 M 
concentrations. Cold peptide (30 µl) was then added to assay tubes 1-21 in triplicate. 
[125I]-ghrelin was then prepared by adding 10 µl to binding buffer (3 ml) and vortexing 
the resultant solution. An aliquot of this [125I]-ghrelin solution (20 µl) was added to an 
empty assay tube and counted on a Cobra™ II Auto-Gamma® gamma counter using 
protocol 3. The volume of [125I]-ghrelin or binding buffer was adjusted as needed in order 
to get 14 000 – 17 000 cpm for every 20 µl aliquot. Having achieved the correct range of 
cpm, the [125I]-ghrelin (20 µl) was pipetted into assay tubes 1-27. All assay tubes were 
then vortexed, capped and immediately agitated (550 rpm, 20 mins, 37oC). After 20 
minutes, tubes 1-21 and 25-27 were spun in a large centrifuge (2800 rpm, 2 mins, 4oC). 
The solution in all of the assay tubes was then transferred to numbered Eppendorf tubes. 
Further binding buffer (200 µl) was added to wash out residual radioactivity from the 
plastic test tubes, and transferred to the Eppendorf tubes. These tubes were then spun 
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again (13 000 xg, 5 mins, 4oC) and placed on ice. The supernatant was removed and the 
cell pellet rinsed with ice-cold Tris-HCl (200 µl, 50 mM, pH 7.4). The Eppendorf tubes 
were then mixed by inversion and spun a final time (13,000 xg, 5 mins, 4oC), cooled on 
ice and supernatant removed a second time. After removing the caps from the Eppendorf 
tubes, they were placed in 12 x 75 mm plastic test tubes and counted using a Cobra™ II 
Auto-Gamma® gamma counter (protocol 3). The binding assay may be summarized as 
follows: 
1) Tubes 1-21: 200 µl binding buffer, 50 µl cells, 30 µl cold peptide, 20 µl [125I]-ghrelin. 
2) Tubes 22-24: 20 µl [125I]-ghrelin. 
3) Tubes 25-27: 20 µl [125I]-ghrelin, 50 µl cells, 230 µl binding buffer. 
4) Tubes 28-30: 300 µl binding buffer.  
4.2.5 Synthesis of Peptidomimetics 
All peptidomimetics were synthesized by the same general procedure as described in 
section 4.2.1 unless otherwise noted. 
LCE00210: H-Aib-His-D-2-Nal-D-Phe-Lys-NH2 (Ipamorelin) 
The product was purified by preparative HPLC (5-80% MeCN + 0.1% TFA). This 
furnished a white powder (20.5 mg, 19%): 1H-NMR (400 MHz, CD3OD); D-2-Nal, D-
Phe, His: δ 7.99 (s, 1H, ArH), 7.80-7.76 (m, 1H, ArH), 7.71 (d, J = 8.6 Hz, 2H, ArH), 
7.56 (s, 1H, ArH), 7.44-7.37 (m, 2H, ArH), 7.32-7.17 (m, 6H, ArH), 6.92 (s, 1H, His 
Hδ), 4.58 (m, 3H, Hα), 3.30-3.21 (m, 1H, D-2-Nal Hβ), 3.15-3.00 (m, 2H, Hβ), 2.96-
2.72 (m, 3H, Hβ), Lys: 4.11 (dd, J = 9.7, 4.2 Hz, 1H, Hα), 2.96-2.72 (m, 2H, Hε), 1.75-
1.64 (m, 1H, Hβ), 1.54-1.40 (m, 3H, Hβ, 2Hδ), 1.05-0.93 (m, 2H, Hγ), Aib: 1.48 (s, 
3H, CH3) 1.44 (s, 3H, CH3) ppm. ESI-LC-MS m/z 356.9 [M + 2H]2+; HRMS (ESI-MS) 
calcd. for C38H50N9O5 [M + H]+ 712.3935, found 712.3959.  
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LCE00211: H-Aib-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 (4-FB-
Ipamorelin) 
Purification by preparative HPLC (20-70% MeCN + 0.1% TFA) yielded a white powder 
(15.4 mg, 15%): 1H-NMR (400 MHz, CD3OD); D-2-Nal, D-Phe, His, 4-FB: δ 7.91 (s, 
1H, ArH), 7.85-7.77 (m, 3H, ArH, 2F-ArH), 7.70 (d, J = 7.9 Hz, 2H, ArH), 7.54 (s, 
1H, ArH), 7.45-7.40 (m, 2H, ArH), 7.29-7.19 (m, 6H, ArH), 7.14-7.07 (m, 2H, 2F-
ArH), 6.93 (s, 1H, His Hδ), 4.65-4.52 (m, 3H, Hα), 3.30-3.27 (m, 1H, Hβ), 3.23 (d, J = 
4.0 Hz, 1H, Hβ), 3.10 (dd, J = 13.5, 7.8 Hz, 1H, Hβ), 3.04-2.74 (m, 3H, Hβ), Lys: 4.12 
(dd, J = 9.8, 4.2 Hz, 1H, Hα), 3.04-2.74 (m, 2H, Hε), 1.77-1.67 (m, 1H, Hβ), 1.58-1.42 
(m, 3H, Hβ, 2Hδ), 1.14-1.03 (m, 2H, Hγ), Aib: 1.50 (s, 3H, CH3), 1.46 (s, 3H, CH3) 
ppm. ESI-LC-MS m/z 418.0 [M + 2H]2+; HRMS (ESI-MS) calcd. for C45H53FN9O6 [M + 
H]+ 834.4103, found 834.4133. 
LCE00217: H-Aib-His-D-2-Nal-D-Phe-Lys(4-FB-AEEA)-NH2 (4-FB-
AEEA-Ipamorelin) 
Peptide purification by preparative HPLC (20-60% MeCN + 0.1% TFA) delivered an off- 
white powder (9.2 mg, 8%): 1H-NMR (400 MHz, CD3OD); His, D-2-Nal, D-Phe, 4-FB: 
δ 7.93 (s, 1H, ArH), 7.86-7.77 (m, 3H, ArH, 2F-ArH), 7.71 (d, J = 8.0 Hz, 2H, ArH), 
7.55 (s, 1H, ArH), 7.46-7.41 (m, 2H, ArH), 7.31-7.18 (m, 6H, ArH), 7.17-7.10 (m, 
2H, F-ArH), 6.94 (s, 1H, His Hδ), 4.65-4.58 (m, 2H, Hα), 4.55 (t, J = 7.5 Hz, 1H, Hα), 
3.16-2.76 (m, 6H, Hβ), Lys: 4.10 (dd, J = 9.7, 4.2 Hz, 1H, Hα), 3.16-2.76 (m, 2H, Hε), 
1.72-1.62 (m, 1H, Hβ), 1.52-1.43 (m, 1H, Hβ), 1.41-1.30 (m, 2H, Hδ), 1.07-0.97 (m, 
2H, Hγ), AEEA linker: 3.93 (s, 2H, NHCOCH2O), 3.65-3.61 (m, 6H, CH2), 3.53 (t, J 
= 5.6 Hz, 2H, CH2), Aib: 1.50 (s, 3H, CH3), 1.47 (s, 3H, CH3) ppm. ESI-LC-MS m/z 
490.4 [M + 2H] 2+; HRMS (ESI-MS) calcd. for C51H64FN10O9 [M + H] + 979.4842, found 
979.4868. 
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LCE00239: H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6) 
Purification by preparative HPLC (15-80% MeCN + 0.1% TFA) gave a white powder 
(19.7 mg, 14%): 1H-NMR (400 MHz, CD3OD); His, D-Trp, Trp, D-Phe: δ 8.46 (s, 1H, 
His Hε), 7.54 (d, J = 7.8 Hz, 1H, ArH), 7.46 (d, J = 7.8 Hz, 1H, ArH), 7.28 (t, J = 7.7 Hz, 
2H, ArH), 7.23-7.13 (m, 4H, ArH), 7.12-6.92 (m, 8H, 7ArH, His Hδ), 4.47 (t, J = 7.4 Hz, 
2H, Trp Hα), 4.35 (t, J = 6.7 Hz, 1H, Hα), 4.28 (t, J = 7.9 Hz, 1H, Hα), 3.22-3.14 (m, 3H, 
Hβ), 3.14-3.02 (m, 3H, Hβ), 2.83 (d, J = 8.6 Hz, 2H, Hβ), Lys: 4.03 (dd, J = 10.3, 3.9 Hz, 
1H, Hα), 2.75 (t, J = 6.8 Hz, 2H, Hε), 1.76-1.63 (m, 1H, Hβ), 1.51-1.39 (m, 3H, Hβ, 2Hδ), 
0.97-0.88 (m, 2H, Hγ), Ala: 3.91 (q, J = 7.2 Hz, 1H, Hα), 0.86 (d, J = 7.3 Hz, 3H, CH3) 
ppm. ESI-LC-MS m/z 437.4 [M + 2H]2+; HRMS (ESI-MS) calcd. for C46H57N12O6 [M + 
H]+ 873.4524 found 873.4531. 
LCE00240: H-Ala-His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (GHRP-1) 
The product was purified by preparative HPLC (15-80% MeCN + 0.1% TFA). This 
yielded a white powder (26.4 mg, 19%): 1H-NMR (400 MHz, CD3OD); His, D-2-Nal, 
Trp, D-Phe: δ 8.41 (s, 1H, His Hε), 7.81-7.71 (m, 3H, ArH), 7.65 (s, 1H, ArH), 7.49 (d, J 
= 7.8 Hz, 1H, ArH), 7.46-7.40 (m, 2H, ArH), 7.35 (dd, J = 8.4, 1.7 Hz, 1H, ArH), 7.31 
(d, J = 8.1 Hz, 1H, ArH), 7.24-7.13 (m, 3H, ArH), 7.10-7.04 (m, 4H, ArH), 7.00 (t, J = 
7.5 Hz, 1H, ArH), 6.89 (d, J = 0.8 Hz, 1H, His Hδ), 4.67-4.60 (m, 2H, Hα), 4.38 (t, J = 7.4 
Hz, 1H, Hα), 4.32 (t, J = 7.7 Hz, 1H, Hα), 3.25-2.68 (m, 8H, Hβ), Ala, Ala: 4.17-4.10 (m, 
1H, Hα), 3.94 (q, J = 7.0 Hz, 1H, Hα), 1.35 (d, J = 7.1 Hz, 3H, CH3), 1.10-1.01 (m, 3H, 
CH3), Lys: 4.17-4.10 (m, 1H, Hα), 3.25-2.68 (m, 2H, Hε), 1.81-1.70 (m, 1H, Hβ), 1.58-
1.45 (3H, Hβ, 2Hδ), 1.10-1.01 (m, 2H, Hγ), ppm. ESI-LC-MS m/z 478.5 [M + 2H]2+; 
HRMS (ESI-MS) calcd. for C51H63N12O7 [M + H]+ 955.4943 found 955.4964.   
LCE00243: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(4-FB)-NH2 (4-FB-G-7039) 
Preparative HPLC (35-80% MeCN + 0.1% TFA) furnished the title compound as a white 
solid (5.90 mg, 6%): 1H-NMR (400 MHz, (CD3)2SO); δ 8.50 (d, J = 8.2 Hz, 1H, NH), 
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8.45 (t, J = 5.5 Hz, 1H, NH), 8.39 (s, 1H, NH), 8.15-8.09 (m, 2H, NH), 8.04 (d, J = 
8.4 Hz, 1H, NH), 7.86-7.82 (m, 2H, F-ArH), 7.82-7.76 (m, 2H, ArH), 7.75-7.66 (m, 
4H, ArH), 7.58 (s, 1H, ArH), 7.48 (s, 1H, ArH), 7.45-7.38 (m, 4H, ArH), 7.31 (dd, J = 
8.5, 1.5 Hz, 1H, ArH), 7.28 (s, 1H, ArH), 7.26 (s, 1H, NH), 7.24-7.17 (m, 5H, ArH), 
7.15-7.08 (m, 2H, ArH), 7.04 (s, 1H, NH), 4.66-4.60 (m, 1H, Hα), 4.60-4.53 (m, 2H, 
Hα), 4.20-4.14 (m, 1H, Lys-Hα), 3.25-3.14 (m, 2H, CH2), 3.13-3.02 (m, 3H, CH2), 
2.98-2.91 (m, 1H, CH2), 2.90-2.83 (m, 1H, CH2), 2.81-2.56 (m, 5H, CH2), 2.30-2.22 
(m, 1H, Inp-Hα), 1.75-1.65 (m, 1H, CH2), 1.62-1.55 (m, 1H, CH2), 1.54-1.43 (m, 6H, 
CH2), 1.38-1.19 (m, 2H, CH2), ppm. ESI-LC-MS m/z 452.5 [M + 4H - F]2+; HRMS 
(ESI-MS) calcd. for C54H59FN7O6 [M + H]+ 920.4511 found 920.4529. 
LCE00244: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2 (MMF-01-113-G) 
Peptide purification by preparative HPLC (25-80% MeCN + 0.1% TFA) delivered a 
white powder (24.9 mg, 23%): 1H-NMR (400 MHz, CD3OD); δ 8.12 (d, J = 8.4 Hz, 
1H, ArH), 7.84 (d, J = 7.8 Hz, 1H, ArH), 7.78-7.72 (m, 2H, ArH), 7.68 (d, J = 8.5 Hz, 
3H, ArH), 7.62-7.46 (m, 5H, ArH), 7.43-7.35 (m, 5H, ArH), 7.30 (d, J = 6.4 Hz, 1H, 
ArH), 7.27-7.21 (m, 2H, ArH), 7.02 (dd, J = 8.4, 1.5 Hz, 1H, ArH), 4.69 (dd, J = 9.4, 
5.4 Hz, 1H, Hα), 4.65-4.55 (m, 2H, Hα), 4.32 (dd, J = 9.4, 4.8 Hz, 1H, Lys-Hα), 3.65 
(dd, J = 14.4, 5.4 Hz, 1H, CH2), 3.20-3.10 (m, 2H, CH2), 3.05-2.94 (m, 3H, CH2), 
2.92-2.80 (m, 5H, CH2), 2.76-2.62 (m, 2H, CH2), 2.30-2.23 (m, 1H, Inp-Hα), 1.92-
1.81 (m, 1H, CH2), 1.75-1.29 (m, 9H, CH2), ppm. ESI-LC-MS m/z 424.8 [M + 2H]2+; 
HRMS (ESI-MS) calcd. for C51H58N7O5 [M + H]+ 848.4499, found 848.4501.       
LCE00245: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2 (G-7039) 
Purification of the peptide proceeded through preparative HPLC (25-80% MeCN + 0.1% 
TFA). The title compound was obtained as a white powder (6.70 mg, 7%): 1H-NMR (400 
MHz, CD3OD); 7.80-7.76 (m, 1H, ArH), 7.74 (dd, J = 6.1, 2.2 Hz, 2H, ArH), 7.70 (dd, J 
= 8.5, 3.5 Hz, 3H, ArH), 7.56 (s, 1H, ArH), 7.50 (s, 1H, ArH), 7.46-7.35 (m, 4H, ArH), 
7.26 (dd, J = 8.5, 1.5 Hz, 1H, ArH), 7.20-7.10 (m, 6H, ArH), 4.66-4.56 (m, 2H, Hα), 4.50 
(dd, J = 9.3, 5.4 Hz, 1H, Hα), 4.30 (dd, J = 9.5, 4.7 Hz, 1H, Lys-Hα), 3.20-2.80 (m, 10H, 
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CH2), 2.78-2.64 (m, 2H, CH2), 2.33-2.24 (m, 1H, Inp-Hα), 1.92-1.82 (m, 1H, CH2), 1.74-
1.65 (m, 1H, CH2), 1.64-1.44 (m, 5H, CH2), 1.44-1.24 (m, 3H, CH2), ppm. ESI-LC-MS 
m/z 399.8 [M + 2H] 2+; HRMS (ESI-MS) calcd. for C47H56N7O5 [M + H]+ 798.4343 found 
798.4339. 
LCE00246: H-Inp-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 (Inp-Thi-4-FB-
Ipamorelin) 
The title peptide was prepared by automated peptide synthesis and purified by preparative 
HPLC (20-80% MeCN + 0.1% TFA). This furnished a white powder (14.0 mg, 13%): 
1H-NMR (400 MHz, CD3OD); His, D-2-Nal, D-2-Thi, 4-FB: δ 8.23 (s, 1H, His Hε), 
7.86-7.81 (m, 2H, F-ArH), 7.80-7.77 (m, 1H, ArH), 7.73 (dd, J = 8.8, 3.3 Hz, 2H, 
ArH), 7.59 (s, 1H, ArH), 7.45-7.39 (m, 2H, ArH), 7.27 (dd, J = 8.5, 1.6 Hz, 1H, ArH), 
7.22 (dd, J = 5.0, 1.2 Hz, 1H, Thi-ArH), 7.15-7.08 (m, 2H, F-ArH), 6.92 (s, 1H, His 
Hδ), 6.91-6.85 (m, 2H, Thi-ArH), 4.61 (dd, J = 10.3, 4.4 Hz, 1H, Hα), 4.53-4.47 (m, 
2H, Hα), 4.22 (dd, J = 9.8, 4.2 Hz, 1H, Lys-Hα), 3.39-3.29 (m, 6H, CH2), 3.26-3.22 
(m, 1H, CH2), 3.01-2.80 (m, 5H, CH2), 2.53-2.44 (m, 1H, Inp-Hα), 1.87-1.50 (m, 8H, 
CH2), 1.35-1.22 (m, 2H, CH2), ppm. ESI-LC-MS m/z 433.8 [M + 2H]2+; HRMS (ESI-
MS) calcd. for C45H53FN9O6S  [M + H]+ 866.3824 found 866.3850. 
LCE00267: H-Aib-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 (Thi-4-FB-
Ipamorelin) 
The title peptide was synthesized by automated peptide synthesis and purified by 
preparative HPLC (20-80% MeCN + 0.1% TFA). This furnished a white solid (4.20 mg, 
4%): 1H-NMR (400 MHz, (CD3)2SO); δ 8.83 (s, 1H, ArH), 8.59 (d, J = 8.1 Hz, 1H, 
NH), 8.42 (t, J = 5.6 Hz, 1H, NH), 8.29 (d, J = 9.3 Hz, 1H, NH), 8.20 (d, J = 8.2 Hz, 
1H, NH), 8.09 (d, J = 8.9 Hz, 1H, NH), 7.99 (s, 2H, NH), 7.86-7.81 (m, 2H, F-ArH), 
7.79-7.75 (m, 1H, ArH), 7.72 (dd, J = 8.7, 3.7 Hz, 2H, ArH), 7.65 (s, 1H, ArH), 7.41-
7.37 (m, 2H, ArH), 7.35-7.31 (m, 2H, ArH, NH), 7.26 (dd, J = 4.8, 1.5 Hz, 1H, Thi-
H), 7.22-7.16 (m, 2H, F-ArH), 7.05 (s, 2H, NH, ArH), 6.88-6.84 (m, 2H, Thi-H), 
4.73-4.66 (m, 1H, Hα), 4.62-4.51 (m, 2H, Hα), 4.19-4.12 (m, 1H, Lys-Hα), 3.21-3.12 
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(m, 4H, 2Hε, 2Hβ), 3.06-2.96 (m, 1H, Hβ), 2.87-2.77 (m, 2H, Hβ), 2.62-2.49 (m, 1H, 
Hβ), 1.66-1.56 (m, 1H, Lys-Hβ), 1.50-1.36 (m, 3H, Lys-Hβ, 2Hδ), 1.26 (s, 3H, CH3), 
1.20-1.10 (m, 2H, Hγ), 1.16 (s, 3H, CH3), ppm. ESI-LC-MS m/z 420.8 [M + 2H]2+; 
HRMS (ESI-MS) calcd. for C43H51FN9O6S  [M + H]+ 840.3667 found 840.3693.  
LCE00268: H-Inp-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 (Inp-4-FB-
Ipamorelin) 
The title peptide was synthesized via automated peptide synthesis and purified by 
preparative HPLC (20-70% MeCN + 0.1% TFA). The title compound was acquired as a 
white solid (6.30 mg, 6%): 1H-NMR (400 MHz, (CD3)2SO); δ 8.79 (s, 1H, His Hε), 8.72 
(s, 1H, NH), 8.44 (dd, J = 10.8, 6.4 Hz, 2H, NH), 8.19 (d, J = 7.8 Hz, 1H, NH), 8.17-
8.10 (m, 2H, NH), 7.87-7.81 (m, 2H, F-ArH), 7.80-7.76 (m, 1H, ArH), 7.71 (d, J = 
7.9 Hz, 2H, ArH), 7.63 (s, 1H, ArH), 7.42-7.35 (m, 2H, ArH), 7.33-7.29 (m, 2H, NH), 
7.22-7.18 (m, 6H, ArH), 7.17-7.11 (m, 2H, F-ArH), 7.06 (s, 1H, NH), 6.96 (s, 1H, His 
Hδ), 4.64-4.56 (m, 1H, Hα), 4.55-4.44 (m, 2H, Hα), 4.15-4.07 (m, 1H, Lys-Hα), 3.19-
3.07 (m, 5H, CH2), 2.94 (dd, J = 13.6, 5.9 Hz, 1H, CH2), 2.87-2.67 (m, 5H, CH2), 
2.58-2.48 (m, 1H, CH2), 2.38-2.29 (m, 1H, Hα), 1.67-1.34 (m, 8H, CH2), 1.15-1.00 
(m, 2H, CH2), ppm. ESI-LC-MS m/z 430.9 [M + 2H]2+; HRMS (ESI-MS) calcd. for 
C47H55FN9O6  [M + H]+ 860.4259 found 860.4284. 
LCE00269: H-Inp-His-D-2-Nal-D-2-Nal-Lys(4-FB)-NH2 (MMF-01-140-
H) 
The title peptide was made by automated peptide synthesis and purified by preparative 
HPLC (20-80% MeCN + 0.1% TFA). This delivered a white solid (11.3 mg, 10%): 1H-
NMR (400 MHz, (CD3)2SO); δ 8.77 (s, 1H, His Hε), 8.51 (d, J = 7.5 Hz, 2H, NH), 8.36 
(t, J = 5.5 Hz, 1H, NH), 8.19-8.10 (m, 2H, NH), 8.05 (d, J = 8.7 Hz, 1H, NH), 7.85-
7.79 (m, 3H, 2F-ArH, ArH), 7.79-7.74 (m, 3H, ArH), 7.73 (s, 1H, ArH), 7.70 (s, 1H, 
ArH), 7.68 (d, J = 2.4 Hz, 2H, ArH), 7.59 (s, 1H, ArH), 7.43-7.35 (m, 5H, ArH), 
7.31-7.27 (m, 2H, NH), 7.20-7.13 (m, 2H, F-ArH), 7.05 (s, 1H, NH), 6.93 (s, 1H, His 
Hδ), 4.67-4.60 (m, 2H, Hα), 4.52-4.44 (m, 1H, Hα), 4.16-4.08 (m, 1H, Lys-Hα), 3.17-
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2.93 (m, 7H, CH2), 2.88-2.66 (m, 4H, CH2), 2.53-2.47 (m, 1H, CH2), 2.34-2.25 (m, 
1H, Hα), 1.63-1.34 (m, 6H, CH2), 1.32-1.23 (m, 2H, CH2), 1.07-0.95 (m, 2H, CH2), 
ppm. ESI-LC-MS m/z 455.9 [M + 2H]2+; HRMS (ESI-MS) calcd. for C51H57FN9O6  [M + 
H]+ 910.4416 found 910.4400. 
LCE00270: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(4-FB)-NH2 (MMF-01-
115-H) 
The product was purified by preparative HPLC (25-90% MeCN + 0.1% TFA) which 
yielded a white powder (9.80 mg, 9%): 1H-NMR (400 MHz, (CD3)2SO); δ 8.64 (d, J = 
8.3 Hz, 1H, NH), 8.46 (t, J = 5.5 Hz, 1H, NH), 8.33 (s, 1H, NH), 8.25 (d, J = 8.4 Hz, 
1H, ArH), 8.13 (d, J = 8.0 Hz, 1H, NH), 8.09 (d, J = 7.5 Hz, 1H, NH), 8.03 (d, J = 8.5 
Hz, 1H, NH), 8.01-7.97 (m, 1H, NH), 7.89 (d, J = 8.2 Hz, 1H, ArH), 7.86-7.80 (m, 
2H, F-ArH), 7.79-7.72 (m, 3H, ArH), 7.71-7.66 (m, 2H, ArH), 7.58-7.50 (m, 4H, 
ArH), 7.44 (d, J = 6.9 Hz, 1H, ArH), 7.42-7.34 (m, 5H, ArH), 7.31-7.25 (m, 2H, 
ArH), 7.21-7.15 (m, 3H, 2F-ArH, ArH), 7.07 (s, 1H, NH), 7.02 (d, J = 8.4 Hz, 1H, 
ArH), 4.72-4.65 (m, 1H, Hα), 4.62-4.50 (m, 2H, Hα), 4.19 (dd, J = 13.3, 8.4 Hz, 1H, 
Lys-Hα), 3.61 (dd, J = 14.3, 3.9, 1H, CH2), 3.24-3.00 (m, 5H, CH2), 2.97-2.89 (m, 1H, 
CH2), 2.82-2.49 (m, 5H, CH2), 2.29-2.19 (m, 1H, Inp-Hα), 1.78-1.66 (m, 1H, CH2), 
1.66-1.54 (m, 1H, CH2), 1.53-1.40 (m, 5H, CH2), 1.40-1.16 (m, 2H, CH2), ppm. ESI-
LC-MS m/z 477.4 [M + 4H - F]2+; HRMS (ESI-MS) calcd. for C58H61FN7O6 [M + H]+ 
970.4667 found 970.4693. 
LCE00272: H-His-D-Trp-Ala-Trp-D-Phe-Lys(4-FB)-NH2 (4-FB-GHRP-
6) 
The product was purified by preparative HPLC (15-80% MeCN + 0.1% TFA). This 
yielded a white powder (9.60 mg, 7%): 1H-NMR (400 MHz, CD3OD); His, D-Trp, Trp, 
D-Phe, 4-FB: δ 8.50 (s, 1H, His Hε), 7.88-7.80 (m, 2H, F-ArH), 7.57 (d, J = 7.9 Hz, 
1H, ArH), 7.49 (d, J = 7.8 Hz, 1H, ArH), 7.30 (t, J = 8.2 Hz, 2H, ArH), 7.26-6.95 (m, 
14H, 13ArH, His Hδ), 4.53-4.46 (m, 2H, Hα), 4.37-4.30 (m, 2H, Hα), 3.26-3.04 (m, 
6H, Hβ), 2.87 (d, J = 8.0 Hz, 2H, Hβ), Lys: 4.04 (dd, J = 10.2, 4.0 Hz, 1H, Hα), 3.26-
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3.04 (m, 2H, Hε), 1.81-1.70 (m, 1H, Hβ), 1.58-1.43 (m, 3H, 2Hδ, Hβ), 1.06-0.97 (m, 
2H, Hγ), Ala: 3.94 (q, J = 7.3 Hz, 1H, Hα), 0.87 (d, J = 7.3 Hz, 3H, CH3) ppm. ESI-
LC-MS m/z 498.4 [M + 2H]2+; HRMS (ESI-MS) calcd. for C53H59FN12O7Na [M + Na]+ 
1017.4511 found 1017.4522.  
LCE00281: H-His-D-Trp-Ala-Trp-D-Phe-Dpr(4-FB)-NH2 (Dpr-4-FB-
GHRP-6) 
Preparative HPLC (25-70% MeCN + 0.1% TFA) gave the title compound as a white 
solid (19.8 mg, 14%): 1H-NMR (400 MHz, CD3OD); His, D-Trp, Trp, D-Phe, 4-FB: δ 
8.58 (d, J = 1.3 Hz, 1H, His Hε), 7.82-7.75 (m, 2H, F-ArH), 7.52 (d, J = 7.9 Hz, 1H, 
ArH), 7.40 (d, J  = 7.9 Hz, 1H, ArH), 7.27 (dd, J  = 8.6, 1.5 Hz, 2H, ArH), 7.15-7.07 
(m, 5H, ArH), 7.06-6.98 (m, 6H, ArH), 6.97-6.89 (m, 3H, 2ArH, His Hδ), 4.54-4.45 
(m, 1H, Hα), 4.44-4.30 (m, 3H, Hα), 3.22-2.98 (m, 6H, Hβ), 2.93-2.74 (m, 2H, Hβ), 
Dpr: 4.54-4.45 (m, 1H, Hα), 3.67 (dd, J = 13.8, 5.6 Hz, 1H, Hβ), 3.54 (dd, J = 13.8, 
7.8 Hz, 1H, Hβ), Ala: 3.93 (q, J = 7.3 Hz, 1H, Hα), 0.86 (d, J = 7.3 Hz, 3H, CH3) ppm.     
ESI-LC-MS m/z 477.4 [M + 2H]2+; HRMS (ESI-MS) calcd. for C50H54FN12O7 [M + H]+ 
953.4223 found 953.4237. 
LCE00282: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 (GHRP-2) 
Purification by preparative HPLC (25-70% MeCN + 0.1% TFA) delivered the title 
peptide as a white powder (19.7 mg, 17%): 1H-NMR (400 MHz, CD3OD); D-2-Nal, Trp, 
D-Phe: δ 7.76 (d, J = 9.2 Hz, 2H, ArH), 7.73 (s, 1H, ArH), 7.65 (s, 1H, ArH), 7.51-7.47 
(m, 1H, ArH), 7.44-7.37 (m, 2H, ArH), 7.35 (dd, J = 8.4, 1.7 Hz, 1H, ArH), 7.25-7.14 
(m, 4H, ArH), 7.09-7.01 (m, 4H, ArH), 7.00 (s, 1H, ArH), 4.77 (dd, J = 10.9, 4.6 Hz, 1H, 
Hα), 4.49 (t, J = 6.8 Hz, 1H, Hα), 4.36 (t, J = 7.6 Hz, 1H, Hα), 3.11 (t, J = 6.7 Hz, 2H, Hβ), 
3.07 (d, J = 4.5 Hz, 1H, Hβ), 2.88-2.70 (m, 3H, Hβ), D-Ala, Ala: 4.23 (q, J = 7.1 Hz, 1H, 
Hα), 3.79 (q, J = 7.0 Hz, 1H, Hα), 1.27 (d, J = 7.2 Hz, 3H, CH3), 1.00 (d, J = 7.1 Hz, 3H, 
CH3), Lys: 4.16 (dd, J = 10.3, 4.1 Hz, 1H, Hα), 2.88-2.70 (m, 2H, Hε), 1.82-1.72 (m, 1H, 
Hβ), 1.56-1.43 (m, 3H, Hβ, 2Hδ), 1.07-0.96 (m, 2H, Hγ), ppm. ESI-LC-MS m/z 409.9 [M 
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+ 2H]2+; HRMS (ESI-MS) calcd. for C45H55N9O6Na [M + Na]+ 840.4204 found 
840.4173.  
LCE00295: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(2-FP)-NH2  (2-FP-G-7039) 
The product was purified by preparative HPLC (30-80% MeCN + 0.1% TFA). This 
yielded a white powder (12.9 mg, 13 %): 1H-NMR (400 MHz, CD3OD); δ 8.22-8.17 (m, 
2H, amide NH), 8.11 (d, J = 7.5 Hz, 2H, amide NH), 8.05 (dd, J = 7.9, 2.0 Hz, 1H, amide 
NH), 7.79-7.66 (m, 6H, ArH), 7.58 (s, 1H, ArH), 7.48 (s, 1H, ArH), 7.44-7.34 (m, 4H, 
ArH), 7.28 (d, J = 8.4 Hz, 1H, ArH), 7.16-7.06 (m, 6H, ArH), 4.96-4.90 (m, 0.5H, HC-
F), 4.82-4.77 (m, 0.5H, HC-F), 4.68-4.56 (m, 2H, Hα), 4.55-4.48 (m, 1H, Hα), 4.28-4.21 
(m, 1H, Lys-Hα), 3.22-3.13 (m, 4H, CH2), 3.12-2.64 (m, 8H, CH2), 2.34-2.26 (m, 1H, 
Inp-Hα), 1.89-1.78 (m, 1H, CH2), 1.76-1.64 (m, 1H, CH2), 1.60-1.23 (m, 11H, 8CH2, 
CH3), ppm. ESI-LC-MS m/z 872.5 [M + H]+; HRMS (ESI-MS) calcd. for C50H59FN7O6 
[M + H]+ 872.4511 found 872.4516. 
LCE00297: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(2-FP)-NH2 (MMF-03-59-
H) 
The title peptide was purified by preparative HPLC (35-80% MeCN + 0.1% TFA). This 
furnished a white powder (7.5 mg, 7 %): 1H-NMR (400 MHz, CD3OD); 8.11 (d, J = 8.4 
Hz, 1H, ArH), 7.82 (d, J = 8.0 Hz, 1H, ArH), 7.75-7.62 (m, 5H, ArH), 7.59-7.42 (m, 5H, 
ArH), 7.41-7.32 (m, 5H, ArH), 7.29-7.23 (m, 2H, ArH), 7.21-7.12 (m, 1H, ArH), 6.99 (d, 
J = 8.4 Hz, 1H, ArH), 4.96-4.89 (m, 0.5H, HC-F), 4.83-4.74 (m, 0.5H, HC-F), 4.73-4.66 
(m, 1H, Hα), 4.66-4.54 (m, 2H, Hα), 4.26 (dd, J = 9.5, 4.8 Hz, 1H, Lys-Hα), 3.65 (dd, J = 
14.5, 4.9 Hz, 1H, CH2), 3.23-3.10 (m, 5H, CH2), 3.03-2.93 (m, 2H, CH2), 2.90-2.81 (m, 
2H, CH2), 2.78-2.62 (m, 2H, CH2), 2.33-2.23 (m, 1H, Inp-Hα), 1.89-1.78 (m, 1H, CH2), 
1.75-1.64 (m, 1H, CH2), 1.58-1.23 (m, 11H, 8CH2, CH3), ppm. ESI-LC-MS m/z 922.5 [M 
+ H]+; HRMS (ESI-MS) calcd. for C54H61FN7O6 [M + H]+ 922.4667 found 922.4651. 
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LCE00298: H-His-D-Trp-Ala-Trp-D-Phe-Dpr-NH2 (Dpr-GHRP-6) 
Purification by preparative HPLC (15-80% MeCN + 0.1% TFA) furnished the title 
peptide as a white powder (4.7 mg, 3 %): 1H-NMR (400 MHz, CD3OD); 8.49 (s, 1H His 
Hε), 7.55 (d, J = 7.9 Hz, 1H, ArH), 7.46 (d, J = 7.9 Hz, 1H, ArH), 7.30 (t, J = 8.6 Hz, 2H, 
ArH), 7.21-7.12 (m, 3H, ArH), 7.11-7.04 (m, 3H, ArH), 7.02-6.92 (m, 5H, ArH), 6.89 (d, 
J = 1.0 Hz, 1H, His Hδ), 4.62 (t, J = 6.8 Hz, 1H, Hα), 4.52 (t, J = 7.9 Hz, 1H, Hα), 4.42-
4.33 (m, 2H, Hα), 4.28 (t, J = 6.7 Hz, 1H, Dpr-Hα), 4.00 (q, J = 7.3 Hz, 1H, Ala-Hα), 
3.24-3.11 (m, 3H, CH2), 3.12-2.92 (m, 5H, CH2), 2.89-2.76 (m, 2H, CH2), 0.94 (d, J = 
7.3 Hz, 3H, Ala-CH3), ppm. ESI-LC-MS m/z 831.4 [M + H]+; HRMS (ESI-MS) calcd. 
for C43H51N12O6 [M + H]+ 831.4055 found 831.4070.      
4.2.6 Synthesis of Small Molecule Triflate Salt 
4-(Tert-butoxycarbonyl)-N,N,N-trimethylbenzenammonium triflate salt 
4-dimethylaminobenzoic acid (1.00 g, 6.05 mmol, 1.0 eq.) was 
added to THF (50 ml) and the resultant mixture stirred and 
cooled to 0°C. After 15 minutes, trifluoroacetic anhydride (1.85 
ml, 13.3 mmol, 2.2 eq.) was added dropwise and the consequent 
blue solution stirred (35 mins). Addition of tBuOH (11.4 ml, 119 mmol, 19.7 eq.) was 
followed by further stirring at room temperature (2 hrs). The solution was then poured 
into saturated NaHCO3 (250 ml) and extracted with DCM (3x 100 ml, 3x 50 ml). The 
combined organic layers were dried (MgSO4), filtered by gravity and residual solvent 
removed by rotary evaporation. This delivered a black oil which was eluted through a 
silica pad (DCM, 60 ml) and solvent removed by concentration in vacuo. The final 
yellow oil (1.12 g, crude) was then re-dissolved in DCM (dry, 30 ml) and cooled to 0°C 
under a blanket of N2. This was followed by the addition of MeOTf (0.86 ml, 7.61 mmol, 
1.5 eq.) and stirring at 0°C (1 hr). The reaction mixture was then poured into an ice-cold 
solution of Et2O (200 ml) which caused instant precipitation of the product salt as a white 
crystalline solid (740 mg, 38%): 1H-NMR (400 MHz, CD3COCD3); δ 8.24 (d, J = 9.3 
Hz, 2H), 8.18 (d, J = 9.3 Hz, 2H), 3.91 (s, 9H, NMe3), 1.60 (s, 9H, OC(CH3)3); 13C-
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NMR (100 MHz, CD3COCD3); δ 205.5 (CO) 163.6 (ArC), 133.7 (ArC), 131.0 (ArC), 
120.9 (ArC), 81.7, 56.9, 27.3 (CH3CO) ppm. ESI-MS m/z 165.1 [C10H13O2]+; HRMS 
(ESI-MS) calcd for C14H22NO2 [M-CF3O3S]+ 236.1651, found 236.1658. 
4.3 Calcium Flux Dose-Response Assay 
This assay was carried out for both lead compounds [1-Nal4,Lys5(4-FB)]G-7039 and 
[Lys5(2-FP)]G-7039 by the EMD Millipore GPCRProfiler® service. Samples of both 
compounds were dissolved in DMSO (1 ml) at a concentration of 250 μM and solubility 
tested in the recommended buffer (Hanks balanced salt solution: 1.26 mM CaCl2, 0.493 
mM MgCl2·6H2O, 0.407 mM MgSO4·7H2O, 5.33 mM KCl, 0.441 mM KH2PO4, 4.17 
mM NaHCO3, 137.9 mM NaCl, 0.338 mM Na2HPO4, 5.56 mM D-Glucose with 20 mM 
HEPES, pH = 7.4 and final concentration of 1.2 % DMSO). If the compound remained 
soluble 15 minutes after addition, samples were shipped to the EMD Millipore 
Corporation (15 Research Park Drive, St. Charles, MO 63304, USA). The assay service 
calculated EC50 values for both peptidomimetics as well as the ghrelin control in terms of 
intracellular Ca2+ release. Human recombinant ghrelin receptor calcium-optimized stable 
cell lines (chem-1 cells) were loaded with a fluorescent calcium dye (Fluo-8 NW from 
ABD Bioquest 21080) and calcium flux detected in response to the agonists by a 
Molecular Devices FLIPRTETRA instrument. The agonist assay was performed for a total 
of 180 seconds. Each assay and assay concentration was performed in duplicate.    
4.4 Computation of Partition Coefficient (LogP) 
The n-octanol/water partition coefficients for all peptidomimetics were calculated using 
two different types of computational software. The first was the ACD/LogP prediction 
software from ACD/ChemSketch (Freeware) version 14.01.113  Here, calculated values 
were based on an experimental data set of over 18,000 logP measurements using an 
additive-constitutive algorithm that took into account contributions from individual 
atoms, fragments and fragment-based intramolecular interactions.112, 113 The second tool 
was XLOGP3 version 3.2.2.114 Starting from the known logP value of a structurally 
similar reference compound, the logP value of the desired compound was determined 
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using a knowledge-based atom-additive model which utilized two correction factors as 
well as 87 atom/group types.114 This model was calibrated using a training set of 8199 
organic compounds and evaluated with two test sets comprising 406 organic compounds 
and 219 oligopeptides respectively.114 All sets contained experimentally determined logP 
values obtained from Hansch and co-workers compilation.114, 121  
4.5 Radiochemistry 
4.5.1 General Information 
Analytical HPLC runs for radioactive and non-radioactive compounds were performed on 
a Sunfire™ LCC-012 RP C-18 column (4.6 x 150 mm). Purification of the radioactive 
compounds was carried out on a Sunfire™ LCC-013 C-18 semi-preparative column (10 x 
150 mm). Breeze™ software v.3.30 (2002 Waters Corporation) was used to analyse 
peptidomimetic and small molecule chromatograms and radio-chromatograms. 
4.5.2 Production of [18F]Fluoride 
The [18F-] anion was produced by the PET cyclotron (St. Joseph’s Health Care London 
Ontario, Canada) as a result of the 18O(p,n)18F reaction involving proton bombardment of 
[18O]H2O. A Waters Sep-Pak® Accell™ Plus Light (46 mg) QMA Carbonate cartridge 
was pre-activated by slowly treating with Milli-Q® water (10 ml) and then flushing with 
air. The radioactive [18F-] anion was then trapped by drawing up the [18O]H2O solution 
containing it through the Sep-Pak.® The left-over enriched water was kept in a separate 
vial for storage and the initial radioactivity of the cartridge measured on a dose calibrator.  
4.5.3 Synthesis of [18F]FBA 
To potassium carbonate (2.0 mg, 0.014 mmol, 2.5 eq.) and Kryptofix 222 (6.0 mg, 0.016  
mmol, 2.8 eq.) was added water (200 μl) and anhydrous MeCN (800 μl) and the resulting 
solution used to elute the Sep-Pak® containing [18F]fluoride into a glass vial. After 
measuring the radioactivity of the vial, the mixture was dried azeotropically (50 °C). The 
drying step was repeated twice more after the drop-wise addition of anhydrous MeCN (1 
ml). A diagonal vial was charged with 4-(tert-butoxycarbonyl)-N,N,N-
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trimethylbenzenammonium triflate salt (2.0 mg, 0.0057 mmol, 1.0 eq.) and the 
aforementioned mixture in DMSO (400 μl). The solution was heated (without stirring) at 
120 °C. After 10 minutes, 5M HCl (1 ml) was added and heating continued for an 
additional 5 minutes. The reaction mixture was then diluted (water, 2 ml) and the crude 
[18F]FBA was trapped in a Sep-Pak® Light tC-18 cartridge (pre-treated with 10 ml of 
ethanol and water) before being extracted with ethanol (0.5 ml) into a reaction vial. The 
ethanol was then removed by the V10 evaporator (36 °C) and the radioactivity measured. 
A co-injection of the cold 4-[19F]-FBA and hot [18F]-FBA 1:1 mixture diluted in water 
(10 μl, 25-90% MeCN + 0.1% TFA gradient system) was used to confirm that the desired 
product had been acquired. This was used in the next step without further purification.    
4.5.4 Attempted Coupling of [18F]FBA to [1-Nal4]G-7039     
The peptide cold standard [1-Nal4,Lys5(4-FB)]G-7039 (0.5 mg) was dissolved in a 
mixture of MeCN (2.5 ml) and water (7.5 ml). This solution was used to check the 
retention time of the cold standard by HPLC (10 μl, gradient system 25-90% MeCN + 
0.1% TFA). [1-Nal4]G-7039 (1.5 mg, 0.0014 mmol, 1.0 eq.) in DMF (200 μl) along with 
HATU in DMF (30 μl, 7.0 x 10-4 mmol, 0.5 eq.), DIPEA in DMF (10 μl, 4.8% solution) 
were added to the [18F]FBA from the previous step and the consequent solution allowed 
to stand at room temperature. After 20 minutes, an analytical HPLC was run in order to 
check the progress of the reaction (25-90% MeCN + 0.1% TFA). As no product had 
formed, DIPEA/DMF (10 μl, 4.8%) and HATU/DMF (30 μl) were added. As this also 
did not yield a fluorobenzoylated product after 20 minutes, this coupling procedure was 
abandoned.   
4.5.5 Synthesis of [18F]SFB 
The crude [18F]FBA was synthesized as described previously. However, trapping of the 
radioactive compound in a Sep-Pak® Light tC-18 cartridge (pre-treated with 10 ml of 
ethanol and 10 ml of water) was followed by elution with MeCN (500 μl) into a mixture 
of EDC (35.0 mg, 0.23 mmol.) and NHS (20.0 mg, 0.17 mmol.) The resultant solution 
was allowed to stand at room temperature. After 10 minutes, the reaction mixture was 
diluted with H2O + 0.1 % TFA (1 ml) and purified by semi-preparative HPLC (35-60% 
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MeCN + 0.1% TFA gradient system, Rt = 9.3 mins) to furnish the prosthetic group 
[18F]SFB (25-90% MeCN + 0.1% TFA, Rt = 5.7 mins) in a radiochemical yield of 59 % 
and radiochemical purity > 99 %. This radioactive compound was dried on the V10 
evaporator (36 °C) before being coupled to the peptidomimetic precursor agonist [1-
Nal4]G-7039. 
4.5.6 Synthesis of [1-Nal4, Lys5(4-[18F]-FB)]G-7039 
To [1-Nal4]G-7039 (1.0 mg, 9.29 x 10-4 mmol., 1.0 eq.) was consecutively added 
[18F]SFB in a 1:1 mixture of MeCN/H2O (200 μl) and DIPEA (5 μl). The consequent 
reaction mixture was heated to 50-70 °C (without stirring). After 15 minutes, crude 18F-
radiolabelled peptidomimetic began to precipitate out of solution as a white solid. The 
solvent was subsequently removed and the solid re-dissolved stepwise with DMF (200 
μl), H2O (400 μl) and MeCN (100 μl). This solution was purified by preparative HPLC 
(35-60% MeCN + 0.1% TFA gradient system, Rt = 12.2 mins) and delivered the title 18F-
radiolabelled peptidomimetic GHS-R1a agonist [1-Nal4,Lys5(4-[18F]-FB)]G-7039 (45-
55% MeCN + 0.1% TFA gradient system, Rt = 6.7 mins) in a decay correct 
radiochemical yield of 52 %, radiochemical purity > 98% and specific activity of 116 
MBq/μmol.  
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Appendix A: Peptidomimetic Chromatograms 
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LCE00210: H-Aib-His-D-2-Nal-D-Phe-Lys-NH2  
 
 
 
LCE00211: H-Aib-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 
 
 
 
 
 
89 
 
LCE00217: H-Aib-His-D-2-Nal-D-Phe-Lys(AEEA-4-FB)-NH2 
 
 
 
LCE00239: H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 
 
 
 
 
90 
 
LCE00240: H-Ala-His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 
 
 
 
LCE00243: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(4-FB)-NH2 
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LCE00244: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2  
 
 
 
LCE00245: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2 
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LCE00246: H-Inp-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 
 
 
 
LCE00267: H-Aib-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 
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LCE00268: H-Inp-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 
 
 
 
LCE00269: H-Inp-His-D-2-Nal-D-2-Nal-Lys(4-FB)-NH2 
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LCE00270: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(4-FB)-NH2 
 
 
 
LCE00272: H-His-D-Trp-Ala-Trp-D-Phe-Lys(4-FB)-NH2 
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LCE00281: H-His-D-Trp-Ala-Trp-D-Phe-Dpr(4-FB)-NH2 
 
 
 
LCE00282: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 
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LCE00295: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(2-FP)-NH2 
 
 
 
LCE00297: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(2-FP)-NH2 
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LCE00298: H-His-D-Trp-Ala-Trp-D-Phe-Dpr-NH2 
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Appendix B: Triflate Salt UHPLC Chromatogram 
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Appendix C: Peptidomimetic 1H-NMR Spectra 
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LCE00210: H-Aib-His-D-2-Nal-D-Phe-Lys-NH2 
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LCE00211: H-Aib-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 
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LCE00217: H-Aib-His-D-2-Nal-D-Phe-Lys(AEEA-4-FB)-NH2  
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LCE00239: H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2  
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LCE00240: H-Ala-His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 
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LCE00243: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(4-FB)-NH2 
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LCE00244: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys-NH2 
1.52.02.53.03.54.04.55.05.56.06.57.07.58.0
f1 (ppm)
PROTON_01
mfowkes
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LCE00245: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys-NH2 
1.41.82.22.63.03.43.84.24.65.05.45.86.26.67.07.47.8
f1 (ppm)
PROTON_MMF-01-107-G_pure_01
mfowkes
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LCE00246: H-Inp-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 
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LCE00267: H-Aib-His-D-2-Nal-D-2-Thi-Lys(4-FB)-NH2 
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LCE00268: H-Inp-His-D-2-Nal-D-Phe-Lys(4-FB)-NH2 
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LCE00269: H-Inp-His-D-2-Nal-D-2-Nal-Lys(4-FB)-NH2 
 
 
 
 
 
 
 
 
 
113 
 
 
LCE00270: H- Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(4-FB)-NH2 
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LCE00272: H-His-D-Trp-Ala-Trp-D-Phe-Lys(4-FB)-NH2 
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LCE00281: H-His-D-Trp-Ala-Trp-D-Phe-Dpr(4-FB)-NH2  
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LCE00282: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 
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LCE00295: H-Inp-D-2-Nal-D-2-Nal-Phe-Lys(2-FP)-NH2 
1.52.02.53.03.54.04.55.05.56.06.57.07.58.0
f1 (ppm)
PROTON_MMF-03-17-H_Fr_15-16_01
mfowkes
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LCE00297: H-Inp-D-2-Nal-D-2-Nal-1-Nal-Lys(2-FP)-NH2 
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LCE00298: H-His-D-Trp-Ala-Trp-D-Phe-Dpr-NH2 
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Appendix D: Triflate Salt 1H-NMR and 13C-NMR 
Spectra 
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1H-NMR Spectrum of 4-(tert-butoxycarbonyl)-N,N,N-
trimethylbenzenammonium triflate salt 
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13C-NMR Spectrum of 4-(tert-butoxycarbonyl)-N,N,N-
trimethylbenzenammonium triflate salt 
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Appendix E: Peptidomimetic Displacement Curves 
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Ghrelin 1-28 
 
LCE00210 
 
125 
 
LCE00211 
 
LCE00217 
 
126 
 
LCE00239 
 
LCE00240 
 
127 
 
LCE00243 
 
LCE00244 
 
128 
 
LCE00245 
LCE00246 
 
 
129 
 
LCE00267 
LCE00268 
 
 
130 
 
LCE00269 
LCE00270 
 
 
131 
 
LCE00272 
 
LCE00281 
 
132 
 
LCE00282 
 
LCE00295 
 
133 
 
LCE00297 
 
LCE00298 
 
134 
 
Curriculum Vitae 
Milan Mrázek Fowkes 
Educational Qualifications: 
2012-2014 Western University (Ontario, Canada) 
 Candidate for Master of Science (M.Sc.) degree in Chemistry (Molecular 
Imaging). 
2007-2011: University of Warwick (Coventry, England) 
 Master of Chemistry, MChem (First class honours). 
 Final year modules: Synthetic Chemistry I-III, Electrochemistry and 
Nanotechnology. 
 Final year project: Bond Rotation and Radical Cyclisation Studies of N-
alkenyl-N-2-bromobenzyl Acetamides. 
Research Experience: 
 2010-11 (20 weeks): Research project on “Bond Rotation and Radical 
Cyclisation Studies of N-alkenyl-N-2-bromobenzyl Acetamides” 
(Supervisor: Dr. Andrew Clark). 
Course Work 
 Mechanistic Organic Chemistry 9553A (Autumn 2012, 90%). 
 Molecular Imaging 9518B (Winter 2012, 95%). 
 Chemistry 9658 Seminar (Winter 2013, 94%). 
Abstracts 
 Fowkes M.M., McGirr R., Dhanvantari S., Luyt, LG. Peptidomimetic 
GHS-R1a Agonists as PET Imaging Agents for Prostate Cancer, CIHR-
STP in Cancer Research & Technology Transfer Research and Education 
Day 2013 [poster presentation]. 
 Fowkes, M.M. Dhanvantari, S. Kovacs, M. Luyt, L.G. Peptidomimetic 
GHS-R1a Agonists as PET Imaging Agents for Prostate Cancer, 97th 
135 
 
Canadian Chemistry Conference and Exhibition (CSC), Vancouver, B.C., 
Canada, June 1-5th 2014 [oral presentation]. 
Teaching Experience 
 2012-2014: Teaching Assistant for Chemistry 2213a. 
 2013-2014: Teaching Assistant for Chemistry 2273a and 2283g. 
 Honours and Awards  
 2012 Western Graduate Research Scholarship. 
 2013 Western Graduate Research Scholarship. 
 2013 Nominated for a Graduate Student Teaching Assistant (GSTA) 
Award. 
 
